protocolSection,derivedSection,hasResults,documentSection
"{'identificationModule': {'nctId': 'NCT06187129', 'orgStudyIdInfo': {'id': 'Nerve ultrasound in neuropathy'}, 'organization': {'fullName': 'Assiut University', 'class': 'OTHER'}, 'briefTitle': 'Evaluation of Nerve Ultrasound in Detecting Clinical and Subclinical Peripheral Neuropathy in Children and Adolescents With Type 1 Diabetes Mellitus', 'officialTitle': 'Evaluation of Nerve Ultrasound in Detecting Clinical and Subclinical Peripheral Neuropathy in Children and Adolescent With Type 1 Diabetes Mellitus'}, 'statusModule': {'statusVerifiedDate': '2024-01', 'overallStatus': 'NOT_YET_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-03-01', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2026-03-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-04', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2023-12-16', 'studyFirstSubmitQcDate': '2023-12-29', 'studyFirstPostDateStruct': {'date': '2024-01-02', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-01-27', 'lastUpdatePostDateStruct': {'date': '2024-01-30', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorFullName': 'Esraa Hosny Dahy', 'investigatorTitle': 'assistant lecturer', 'investigatorAffiliation': 'Assiut University'}, 'leadSponsor': {'name': 'Esraa Hosny Dahy', 'class': 'OTHER'}}, 'descriptionModule': {'briefSummary': 'Aim of study:\n\nTo evaluate accuracy of nerve ultrasound in detecting clinical and subclinical peripheral neuropathy in children and adolescents diagnosed with type 1 diabetes melitus .', 'detailedDescription': 'Introduction Type 1 diabetes (T1D) is a chronic disease with long-term vascular complications which include nephropathy, retinopathy, neuropathy, and macrovascular disease . In childhood and adolescence, early functional and structural vascular related abnormalities may be present a few years after the onset of the disease, so In this period intensive education and treatment may prevent or delay the onset and progression of complications.\n\nDiabetic neuropathy (DN) is an important complication in patients with diabetes since it is related to mortality, morbidity, and a decrease in the quality of life ,as it is associated with neuropathic pain, foot ulceration, and subsequently gangrene and amputation.\n\nTypical DPN is a chronic, nerve-length-dependent, distal symmetrical sensorimotor polyneuropathy (DSPN) and is considered as the most common form among diabetic neuropathies .\n\nDPN can be classified into subclinical and clinical stages; based on history with sensory disturbances (possible); symptoms and/or signs of nerve dysfunction (probable); symptoms and/or signs plus abnormal gold standard test (confirmed); abnormal gold standard test (subclinical).\n\nSubclinical neuropathy is defined as asymptomatic peripheral neuropathy, which is one of the common complications of patients with diabetes mellitus (DM). There is considerable uncertainty about the prevalence of diabetic peripheral neuropathy (DPN) in pediatric populations, which is probably due to the lack of large epidemiological studies performed on pediatric patients with DM, who often show few symptoms of neurological involvement.\n\nEvidence from western studies have suggested that a quarter of children and adolescents with type 1 diabetes have clinical or subclinical evidence of nerve injury at diagnosis , The prevalence of peripheral neuropathy in known children with T1DM is reported to be as high as 50% .\n\nMany risk factors have been suggested for peripheral neuropathy, such as the duration of diabetes, age at onset, height, puberty, positive family history, and diabetic complications of puberty .\n\nThe effect of chronic hyperglycemia is mediated by the increase of the intracellular level of glucose and sorbitol, which eventually leads to oxidative stress and the generation of free radicals, which damage intracellular macromolecules. In addition, chronic hyperglycemia induces the formation of advanced glycation end products (AGEs), which modify the structure of myelin, leading to axonal degeneration.\n\nCurrently, the diagnosis of DPN is mainly based on characteristic symptoms and signs. Nerve conduction studies (NCS) is one of the gold standard techniques for diagnosing DPN . It evaluates the occurrence and development of DPN by detecting the ability of peripheral nerve to transmit electrical signals in patients with DN. NCS has the characteristics of being quantifiable, objective, and sensitive, but it has the following disadvantages: time-consuming, high cost, poor experience, and the need for professional doctors to operate.\n\nAlthough there are no guidelines on screening subclinical diabetic neuropathy, nerve conduction study (NCS) is the most common tool used for diagnosing it.\n\nThe pattern of nerve dysfunction has varied in neurophysiological studies on pediatric populations .Some studies found that subclinical sensory affection is prevalent. And others found that subclinical motor affection more common.\n\nHigh-resolution ultrasound is of growing importance as a painless method complementary to nerve conduction studies in the workup of disorders of the peripheral nervous system, especially in children and adolescents .Cross-sectional area, echogenicity, morphology of the individual nerve fascicles, thickness of the epineurium, vascularization and mobility of the nerve are the main parameters evaluated with nerve ultrasound in polyneuropathies.\n\nHigh-frequency ultrasound was first used in the clinical diagnosis of DPN as a supplement to NCS. It measures the size, blood vessels, echo, and mobility of the diseased nerve to show the damage of the nerve tissue, which can effectively improve the diagnostic efficiency of DPN and reduce the missed diagnosis rate and the misdiagnosis rate . In patients with DPN, the cross sectional area (CSA) and longitudinal section of the nerve are increased, and the echogenicity of the nerve, the boundary ambiguity, and the blood flow in the nerve are also significantly increased. The mean CSA in the examined nerves was higher in moderate to severe DPN than the mild DPN .\n\nHigh resolution ultrasound has unique diagnostic advantages for early or subclinical neuropathy. High-frequency ultrasound can detect subclinical involvement of peripheral nerves and abnormalities in patients with normal electrical diagnosis .'}, 'conditionsModule': {'conditions': ['Peripheral Neuropathy']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'CROSS_SECTIONAL'}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'diabetic children and adolescent with type 1 diabetes', 'description': 'nerve ultrasound and nerve conduction study', 'interventionNames': ['Device: nerve ultrasound']}, {'label': 'healthy age matched group', 'description': 'nerve ultrasound', 'interventionNames': ['Device: nerve ultrasound']}], 'interventions': [{'type': 'DEVICE', 'name': 'nerve ultrasound', 'description': 'nerve ultrasound', 'armGroupLabels': ['diabetic children and adolescent with type 1 diabetes', 'healthy age matched group'], 'otherNames': ['nerve conduction study']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'cross sectional area of peripheral nerves using nerve ultrasound', 'description': 'To evaluate accuracy of nerve ultrasound in detecting clinical and subclinical peripheral neuropathy in children and adolescents diagnosed with type 1 diabetes melitus .', 'timeFrame': 'baseline'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n\\- 1.Children and adolescents aged 8-17 y diagnosed as type 1 DM according to American diabetes association ( ADA) (17) .\n\n2.On multiple injection or insulin pump for at least 5 years or more. 3.Patients are free from acute complication like diabetes ketoacidosis (DKA), symptomatic hypoglycemia, or infection for at least one month before enrollment in the study.\n\nExclusion Criteria:\n\n* 1.Age less than 8 years or more than 17 years. 2.Diabetes other than T1DM . 3.Patients with known neuropathy of any other cause rather than diabetes. 4.Diabetic children with thyroid dysfunction ,coelic disease or anemia.', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '8 Years', 'maximumAge': '17 Years', 'stdAges': ['CHILD'], 'studyPopulation': '1. Children and adolescents aged 8-17 y diagnosed as type 1 DM according to American diabetes association ( ADA) (17) .\n2. On multiple injection or insulin pump for at least 5 years or more.\n3. Patients are free from acute complication like diabetes ketoacidosis (DKA), symptomatic hypoglycemia, or infection for at least one month before enrollment in the study.', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Esraa H Hosny Dahy Hassan', 'role': 'CONTACT', 'phone': '01064080903', 'email': 'esraahosny@aun.edu.eg'}]}, 'referencesModule': {'references': [{'pmid': '30079595', 'type': 'BACKGROUND', 'citation': 'Donaghue KC, Marcovecchio ML, Wadwa RP, Chew EY, Wong TY, Calliari LE, Zabeen B, Salem MA, Craig ME. ISPAD Clinical Practice Consensus Guidelines 2018: Microvascular and macrovascular complications in children and adolescents. Pediatr Diabetes. 2018 Oct;19 Suppl 27(Suppl 27):262-274. doi: 10.1111/pedi.12742. No abstract available.'}, {'pmid': '20823346', 'type': 'BACKGROUND', 'citation': 'Charles M, Soedamah-Muthu SS, Tesfaye S, Fuller JH, Arezzo JC, Chaturvedi N, Witte DR; EURODIAB Prospective Complications Study Investigators. Low peripheral nerve conduction velocities and amplitudes are strongly related to diabetic microvascular complications in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care. 2010 Dec;33(12):2648-53. doi: 10.2337/dc10-0456. Epub 2010 Sep 7.'}, {'pmid': '31083769', 'type': 'BACKGROUND', 'citation': 'Kallinikou D, Soldatou A, Tsentidis C, Louraki M, Kanaka-Gantenbein C, Kanavakis E, Karavanaki K. Diabetic neuropathy in children and adolescents with type 1 diabetes mellitus: Diagnosis, pathogenesis, and associated genetic markers. Diabetes Metab Res Rev. 2019 Oct;35(7):e3178. doi: 10.1002/dmrr.3178. Epub 2019 Jun 6.'}, {'pmid': '21695763', 'type': 'BACKGROUND', 'citation': ""Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels GJ, Bril V, Feldman EL, Litchy WJ, O'Brien PC, Russell JW; Toronto Expert Panel on Diabetic Neuropathy. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011 Oct;27(7):620-8. doi: 10.1002/dmrr.1226.""}, {'pmid': '20876709', 'type': 'BACKGROUND', 'citation': 'Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010 Oct;33(10):2285-93. doi: 10.2337/dc10-1303.'}, {'pmid': '35949448', 'type': 'BACKGROUND', 'citation': 'Altuwaijri WA, Almutair AN, AlAlwan IA, Almahdi MJ, Almasoud SD. Subclinical Neuropathy in Children With Type I Diabetes Mellitus: Tertiary Care Centre Experience. Cureus. 2022 Aug 8;14(8):e27765. doi: 10.7759/cureus.27765. eCollection 2022 Aug.'}, {'pmid': '29429781', 'type': 'BACKGROUND', 'citation': 'Walter-Holiner I, Barbarini DS, Lutschg J, Blassnig-Ezeh A, Zanier U, Saely CH, Simma B. High Prevalence and Incidence of Diabetic Peripheral Neuropathy in Children and Adolescents With Type 1 Diabetes Mellitus: Results From a Five-Year Prospective Cohort Study. Pediatr Neurol. 2018 Mar;80:51-60. doi: 10.1016/j.pediatrneurol.2017.11.017. Epub 2017 Dec 13.'}, {'pmid': '34764937', 'type': 'BACKGROUND', 'citation': 'Yu Y. Gold Standard for Diagnosis of DPN. Front Endocrinol (Lausanne). 2021 Oct 26;12:719356. doi: 10.3389/fendo.2021.719356. eCollection 2021.'}, {'pmid': '19893645', 'type': 'BACKGROUND', 'citation': 'Misra UK, Kalita J, Nair PP. Diagnostic approach to peripheral neuropathy. Ann Indian Acad Neurol. 2008 Apr;11(2):89-97. doi: 10.4103/0972-2327.41875.'}, {'pmid': '15713353', 'type': 'BACKGROUND', 'citation': 'Karsidag S, Morali S, Sargin M, Salman S, Karsidag K, Us O. The electrophysiological findings of subclinical neuropathy in patients with recently diagnosed type 1 diabetes mellitus. Diabetes Res Clin Pract. 2005 Mar;67(3):211-9. doi: 10.1016/j.diabres.2004.07.017.'}, {'pmid': '26905353', 'type': 'BACKGROUND', 'citation': 'Toopchizadeh V, Shiva S, Khiabani NY, Ghergherechi R. Electrophysiologic pattern and prevalence of subclinical peripheral neuropathy in children and adolescents with type I diabetes mellitus in Iran. Saudi Med J. 2016 Mar;37(3):299-303. doi: 10.15537/smj.2016.3.13625.'}, {'pmid': '34109557', 'type': 'BACKGROUND', 'citation': 'Singh DP, Singh P, Sharma S, Aneja S, Seth A. Point Prevalence of Peripheral Neuropathy in Children and Adolescents with Type 1 Diabetes Mellitus. Indian J Pediatr. 2022 Mar;89(3):220-225. doi: 10.1007/s12098-021-03742-4. Epub 2021 Jun 10.'}, {'pmid': '37621670', 'type': 'BACKGROUND', 'citation': 'Yusuf I, Mork H, Erdlenbruch B, Schellinger PD, Philipps J. Nerve ultrasound reference values in children and adolescents: Echogenicity and influence of anthropometric factors including hand volume. J Cent Nerv Syst Dis. 2023 Aug 21;15:11795735231195778. doi: 10.1177/11795735231195778. eCollection 2023.'}, {'pmid': '37382111', 'type': 'BACKGROUND', 'citation': 'Pitarokoili K, Gold R, Fisse AL. Nerve ultrasound for the diagnosis and follow-up of peripheral neuropathies. Curr Opin Neurol. 2023 Oct 1;36(5):373-381. doi: 10.1097/WCO.0000000000001183. Epub 2023 Jun 23.'}, {'pmid': '27028140', 'type': 'BACKGROUND', 'citation': 'Hajas G, Kissova V, Tirpakova A. A 10-yr follow-up study for the detection of peripheral neuropathy in young patients with type 1 diabetes. Pediatr Diabetes. 2016 Dec;17(8):632-641. doi: 10.1111/pedi.12382. Epub 2016 Mar 29.'}, {'pmid': '30093549', 'type': 'BACKGROUND', 'citation': 'Chiang JL, Maahs DM, Garvey KC, Hood KK, Laffel LM, Weinzimer SA, Wolfsdorf JI, Schatz D. Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association. Diabetes Care. 2018 Sep;41(9):2026-2044. doi: 10.2337/dci18-0023. Epub 2018 Aug 9. No abstract available.'}, {'pmid': '31032944', 'type': 'BACKGROUND', 'citation': 'Ryan CS, Conlee EM, Sharma R, Sorenson EJ, Boon AJ, Laughlin RS. Nerve conduction normal values for electrodiagnosis in pediatric patients. Muscle Nerve. 2019 Aug;60(2):155-160. doi: 10.1002/mus.26499. Epub 2019 May 11.'}, {'pmid': '32411079', 'type': 'BACKGROUND', 'citation': 'Grimm AS, Schubert C, Grimm A, Stahl JH, Kupper H, Horber V, Kegele J, Willikens S, Wittlinger J, Serna-Higuita L, Winter N, Groeschel S. Normative Observational Nerve Ultrasound Values in School-Age Children and Adolescents and Their Application to Hereditary Neuropathies. Front Neurol. 2020 Apr 28;11:303. doi: 10.3389/fneur.2020.00303. eCollection 2020.'}]}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D010523', 'term': 'Peripheral Nervous System Diseases'}], 'ancestors': [{'id': 'D009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000092184', 'term': 'Nerve Conduction Studies'}], 'ancestors': [{'id': 'D003943', 'term': 'Diagnostic Techniques, Neurological'}, {'id': 'D019937', 'term': 'Diagnostic Techniques and Procedures'}, {'id': 'D003933', 'term': 'Diagnosis'}, {'id': 'D004568', 'term': 'Electrodiagnosis'}]}}",False,
"{'identificationModule': {'nctId': 'NCT06330480', 'orgStudyIdInfo': {'id': 'Check@Home'}, 'organization': {'fullName': 'Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)', 'class': 'OTHER'}, 'briefTitle': 'Check@Home: General Population Screening for Early Detection of Atrial Fibrillation and Chronic Kidney Disease', 'officialTitle': 'Check@Home: General Population Screening for Early Detection of Atrial Fibrillation and Chronic Kidney Disease'}, 'statusModule': {'statusVerifiedDate': '2025-05', 'overallStatus': 'ENROLLING_BY_INVITATION', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-05-14', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2028-06-01', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2028-11-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-03-07', 'studyFirstSubmitQcDate': '2024-03-19', 'studyFirstPostDateStruct': {'date': '2024-03-26', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-05-13', 'lastUpdatePostDateStruct': {'date': '2025-05-16', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorFullName': 'Prof. Dr. Folkert W. Asselbergs', 'investigatorTitle': 'Prof. Dr. F. W. Asselbergs', 'investigatorAffiliation': 'Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)'}, 'leadSponsor': {'name': 'Prof. Dr. Folkert W. Asselbergs', 'class': 'OTHER'}, 'collaborators': [{'name': 'Dutch Cardiovascular Alliance', 'class': 'UNKNOWN'}, {'name': 'University Medical Center Groningen', 'class': 'OTHER'}, {'name': 'Dutch Heart Foundation', 'class': 'OTHER'}, {'name': 'Dutch Kidney Foundation', 'class': 'OTHER'}, {'name': 'Dutch Diabetes Research Foundation', 'class': 'OTHER'}, {'name': 'Maastricht University', 'class': 'OTHER'}, {'name': 'AstraZeneca', 'class': 'INDUSTRY'}, {'name': 'UMC Utrecht', 'class': 'OTHER'}, {'name': 'Radboud University Medical Center', 'class': 'OTHER'}, {'name': 'Siemens Healthineers Nederland BV', 'class': 'UNKNOWN'}, {'name': 'University of Twente', 'class': 'OTHER'}, {'name': 'Roche Diagnostics Nederland BV', 'class': 'UNKNOWN'}, {'name': 'Happitech BV', 'class': 'UNKNOWN'}, {'name': 'Stichting Radboud Universiteit', 'class': 'UNKNOWN'}, {'name': 'Stichting Netherlands Heart Institute', 'class': 'UNKNOWN'}, {'name': 'Topicus.Healthcare BV', 'class': 'UNKNOWN'}, {'name': 'Amsterdam UMC, location AMC', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'The aim of the Check@Home consortium is to set up a roadmap and infrastructure for a program to early detect atrial fibrillation and chronic kidney disease in the general population.\n\nThis will be a population-based screening with a phased implementation and an iterative design in four regions in the Netherlands (Breda, Utrecht, Arnhem, Eindhoven). In total, a random sample of 160,000 people (aged 50-75 years) will be invited to participate in the study and another random sample of 160,000 people with the same characteristics will be included in the control group in which no screening will be offered.\n\nThe overall screening program will consist of three phases: a home-based testing phase, diagnostic screening phase, and a treatment phase:\n\n* Phase 1: Subjects will be invited for a home-based screening that includes home-based testing; urine collection for detection of elevated albuminuria, and a heart rhythm measurement using a smartphone app for detection of atrial fibrillation.\n* Phase 2: Depending on the results on these home-based tests, subjects will be invited for further screening in a diagnostic screening facility. During this visit, physical data will be collected (height, weight, waist circumference, blood pressure, heart rhythm), blood will be drawn, and urine will be collected for the assessment of parameters that are indicative of a cardiovascular disease, chronic kidney disease, type 2 diabetes or their risk factors. Participants will receive a questionnaire that include questions on demographics, educational level, disease history, medication use, health literacy, and quality of life.\n* Phase 3: Based on the results of the diagnostic screening, participants may be referred to their general practitioner for appropriate treatment (lifestyle advice/medication) according to the prevailing guidelines.\n\nThe primary study outcomes are:\n\nOverall effectiveness of population based screening on atrial fibrillation and chronic kidney disease in subjects aged 50-75 years, based on:\n\n* Participation rate of different screening strategies and phases;\n* Yield of the screening (number of subjects with (newly) diagnosed disease and risk factors);\n* Effectiveness of the atrial fibrillation screening, compared with standard care, based on the incidence of ischemic stroke);\n* Effectiveness of the albuminuria screening, compared with standard care, based on the incidence of kidney failure events and Major Adverse Cardiovascular Events (MACE).', 'detailedDescription': 'Background:\n\nCurrently, in the Netherlands there is no structured national approach for the early detection of cardiovascular disease, kidney disease, and type 2 diabetes in the general population, despite the social and economic impact of these disorders. Detecting these chronic conditions at an early stage could allow for adequate and early treatment to prevent the progression of these conditions and their complications, thereby reducing the societal and economic burden caused by these chronic diseases.\n\nObjective of the study:\n\nTo investigate whether population-based screening of subjects aged 50-75 years can contribute to early detection and treatment of atrial fibrillation and chronic kidney disease (defined by elevated albuminuria), and thereby can contribute to prevention of the morbidity and mortality related to these diseases. This will be done by evaluating the participation rate, yield, and (cost-)effectiveness of the screening compared with standard care. Furthermore, the project aims to evaluate options for broader screening, including the early detection of heart failure, coronary artery disease, and type 2 diabetes.\n\nStudy design:\n\nThis will be a population-based screening with a phased implementation and an iterative design in four regions in the Netherlands (Breda, Utrecht, Arnhem, Eindhoven).\n\nParticipants will be invited for a home-based screening (phase 1) that includes home-based testing; urine collection for detection of elevated albuminuria as indicator of chronic kidney disease, and a heart rhythm measurement using a smartphone app for detection of atrial fibrillation. Both home-based tests will be performed with CE-marked medical devices used according to their intended use. A subset of the population will also receive a short questionnaire. Depending on the results of the home-based tests, subjects might be invited for further screening in a diagnostic screening facility (phase 2). During this visit, physical data (height, weight, waist circumference, blood pressure, heart rhythm) will be collected, blood will be drawn, and urine will be collected for the assessment of parameters that are indicative of a cardiovascular disease, chronic kidney disease, type 2 diabetes or their risk factors. Participants will receive a questionnaire that includes questions on demographics, educational level, disease history, medication use, health literacy, and quality of life. Based on the results of the diagnostic screening, participants may be referred to their general practitioner for appropriate treatment (lifestyle advice/medication) according to the prevailing guidelines. It is planned that in a future protocol amendment an alternative treatment trajectory will be added in which participants may receive further treatment in the diagnostic screening facility.\n\nStudy population:\n\nIn total, a random sample of 160,000 people (aged 50-75 years) living in one of the four selected regions in the Netherlands will be invited to participate in the study. Another random sample of 160,000 people (aged 50-75 years) living in one of the four selected regions in the Netherlands will be included in the control group in which no screening will be offered.'}, 'conditionsModule': {'conditions': ['Atrial Fibrillation', 'Chronic Kidney Diseases', 'Diabetes Mellitus, Type 2'], 'keywords': ['Population-based screening']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Check@Home is a population-based screening with a phased assessment and implementation using an iterative design executed consecutively in four regions in the Netherlands.', 'primaryPurpose': 'SCREENING', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 320000, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Intervention group', 'type': 'OTHER', 'description': 'This group will be invited for the screening', 'interventionNames': ['Other: Intervention group']}, {'label': 'Control group', 'type': 'NO_INTERVENTION', 'description': 'This group will not be invited for the screening'}], 'interventions': [{'type': 'OTHER', 'name': 'Intervention group', 'description': 'Subjects will be invited for a home-based screening (phase 1) that includes home-based testing; urine collection for detection of elevated albuminuria, and a heart rhythm measurement for detection of atrial fibrillation. Both home-based tests will be performed with CE-marked medical devices used according to their intended use. A subset of the population will also receive a short questionnaire. Depending on the results of the home-based tests, subjects might be invited for further screening in a diagnostic screening facility (phase 2), that includes collection of physical data, blood, and urine for the assessment of parameters that are indicative of cardiovascular disease, chronic kidney disease, diabetes type 2 or their risk factors. Participants will also receive a questionnaire. Based on the results of the diagnostic screening, participants may be referred to their GP for appropriate treatment according to the prevailing guidelines (phase 3)', 'armGroupLabels': ['Intervention group']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Participation rate of the atrial fibrillation and albuminuria screening', 'description': ""* Participation rate of the home-based screening phase will be defined as the number of persons who completed the home-based screening phase relative to the number of persons invited in the corresponding arm (intention-to-screen);\n* Participation rate of the diagnostic screening phase will be defined as the number of persons who completed the diagnostic screening phase relative to the number of persons invited for the diagnostic screening phase in the corresponding arm (in participants invited based on an 'abnormal' result in the home-based screening phase, i.e. either confirmed elevated albuminuria or an irregular heart rhythm);\n* Participation rate of the treatment phase will be defined as the number of persons who completed the care initiation phase (i.e., number of participants visiting their GP; or - in future phases of the screening - the diagnostic center) relative to the number of persons referred for treatment in the corresponding arm (intention-to-screen)."", 'timeFrame': '1 year after screening period'}, {'measure': 'Yield of the atrial fibrillation and albuminuria screening', 'description': '* Yield of home-based screening: number of participants tested positive (i.e., either confirmed positive urine test and/or abnormal heart rhythm test) relative to the number of persons participating in the corresponding arm (per-protocol analysis) and to the number of persons invited in the corresponding arm (intention-to-screen analysis);\n* Yield of diagnostic screening: number of participants with (newly) diagnosed cardiovascular or chronic kidney disease, diabetes or risk factors, relative to the number of persons participating in the corresponding arm (per-protocol analysis) and to the number of persons invited in the corresponding arm (intention-to-screen analysis);\n* Yield of treatment phase: number of participants completing the treatment phase relative to the number of persons participating in the corresponding arm (per-protocol analysis) and to the number of persons invited to the treatment phase in the corresponding arm (intention-to-screen analysis).', 'timeFrame': '1 year after screening period'}, {'measure': 'Effectiveness of the atrial fibrillation screening', 'description': 'Effectiveness of the atrial fibrillation screening (the home-based screening program and follow-up strategy) will be based on the incidence of (fatal and non-fatal) ischemic stroke. This will be evaluated by comparing the event rates in the intervention group (the sample of 160,000 subjects invited for screening) and the control group (the sample of 160,000 subjects not invited for screening).', 'timeFrame': 'Up to 10 years follow-up after screening period'}, {'measure': 'Effectiveness of the albuminuria screening', 'description': ""Effectiveness of the albuminuria screening (the home-based screening program and follow-up strategy), based on the incidence of the composite outcome of kidney failure events (defined as start of dialysis, receiving a kidney transplant, or death due to kidney failure without having started kidney function replacement treatment) and MACE (for albuminuria screening defined as cardiovascular mortality, stroke, and myocardial infarction, including CABG and PCI).\n\nThis will be evaluated by comparing the event rates in the population screened positive for elevated albuminuria and followed-up based on this result (i.e., participants in the standard strategy and other alternative strategies) and in the population screened positive for elevated albuminuria - at a later timepoint - and not followed-up based on this result (i.e., participants in 'alternative strategy B')."", 'timeFrame': 'Up to 10 years follow-up after screening period'}], 'secondaryOutcomes': [{'measure': 'Effectiveness of the atrial fibrillation screening based on incidence of MACE events', 'description': 'Effectiveness of the atrial fibrillation screening (the home-based screening program and follow-up strategy), based on the incidence of MACE (for atrial fibrillation screening defined as cardiovascular mortality, stroke, non-hemorrhagic stroke, and myocardial infarction, including CABG and PCI).\n\nThis will be evaluated by comparing the event rates in the intervention group (the sample of 160,000 subjects invited for screening) and the control group (the sample of 160,000 subjects not invited for screening).', 'timeFrame': 'Up to 10 years follow-up after screening period'}, {'measure': 'Effectiveness of the albuminuria screening based on incidence each individual MACE component', 'description': ""Effectiveness of the albuminuria screening (the home-based screening program and follow-up strategy), based on each individual component defining MACE (for albuminuria screening defined as cardiovascular mortality, stroke, and myocardial infarction, including CABG and PCI).\n\nThis will be evaluated by comparing the event rates in the in the population screened positive for elevated albuminuria and followed-up based on this result (i.e., participants in the standard strategy and other alternative strategies) and in the population screened positive for elevated albuminuria - at a later timepoint - and not followed-up based on this result (i.e., participants in 'alternative strategy B')."", 'timeFrame': 'Up to 10 years follow-up after screening period'}, {'measure': 'Safety of the atrial fibrillation screening', 'description': 'Safety of the atrial fibrillation screening (the home-based screening program and follow-up strategy), based on the incidence of the composite outcome of (fatal and non-fatal) hemorrhagic stroke, other major bleeding events leading to hospitalization (including but not limited to intracranial bleeds, sight-threatening eye bleeds, and serious gastrointestinal bleeding), and all cause-mortality.\n\nThis will be evaluated by comparing the event rates in the intervention group (the sample of 160,000 subjects invited for screening) and the control group (the sample of 160,000 subjects not invited for screening).', 'timeFrame': 'Up to 10 years follow-up after screening period'}, {'measure': 'Cost-effectiveness of screening strategies compared with standard of care: treatment effectiveness based on literature.', 'description': 'An individual level simulation model will be developed to estimate the lifetime effects of the screening strategies for the detection of atrial fibrillation and chronic kidney disease by comparing the corresponding expected incidences of cardiovascular and chronic kidney disease, diabetes and their complications and endpoints with standard care. Incremental effectiveness will be calculated, expressed in QALYs gained for the different screening strategies. Costs will be calculated by multiplying resource use with the corresponding unit costs. The ICER between screening strategies and no screening, expressed in costs per QALY gained, will be calculated over a short-time (5-10 years after screening) and a lifetime time horizon. Finally, we will assess the chance that screening is cost-effective for a range of willingness-to-pay threshold values (range €20,000-€80,000 per QALY) and at which threshold for the screening costs screening would have a chance of ≥90% to be cost-effective.', 'timeFrame': 'Up to 10 years follow-up after screening period'}, {'measure': 'Cost-effectiveness of screening strategies compared to standard of care: treatment effectiveness based on actual observed event rates', 'description': 'Using registry data, we will compare event rates between the intervention group (invited for screening) and the control group (not invited for screening) 5 and 10 years after the screening. Currently foreseen is that the data on fatal and non-fatal cardiovascular disease (according to the MACE criteria; based on corresponding ICD-10 codes) and renal events (dialysis and transplantation; based on corresponding ICD-10 codes) will be obtained and compared. These data will be obtained by linkage with CBS (i.e., Dutch Hospital Data, Vektis, Zorginstituut Nederland), Zorgverzekeraars Nederland, Pharmo, National Heart Registry, and general practitioner registries. These data will be input for the health economic simulation model, replacing earlier estimates of treatment effectiveness and treatment adherence. The ICER and estimation of the likelihood of screening being cost-effective will be repeated using this new and more accurate evidence.', 'timeFrame': 'Up to 10 years follow-up after screening period'}], 'otherOutcomes': [{'measure': 'False-positive rate, false-negative rate, sensitivity, specificity, positive predictive screening on atrial fibrillation and albuminuria screening.', 'description': '* False-positives: participants with an abnormal home-based test result, but normal test results at the diagnostic screening visit.\n* False-negatives: participants with normal home-based test results, but abnormal test results at the diagnostic screening visit.\n* Sensitivity: the ability of the home-based test to correctly identify participants with the disease.\n* Specificity: the ability of the home-based test to correctly identify participants without the disease.\n* Positive predictive value: the proportion of participants correctly diagnosed as positive (having the disease) out of all participants with a positive test result.\n* Negative predictive value: the proportion of participants correctly diagnosed as negative (not having the disease) out of all participants with a negative test result.', 'timeFrame': 'Up to 10 years follow-up after screening period'}, {'measure': 'Characteristics of responders and non-responders', 'description': 'Characteristics of responders and non-responders, and differences between them, will be analyzed using descriptive statistics per screening strategy. For health literacy descriptive statistical analyses will be performed on the HLS-Q12 questionnaire (per item and/or combined). Future exploratory analyses may evaluate whether health literacy is related to participation rate, health outcomes, and or characteristics of participants and non-participants (such as age and socioeconomic indicators of the neighborhood). In addition, facilitators and barriers for participation will be studied taking into account qualitative data on experiences, considerations and enabling and constraining conditions, collected both in participants and non-participants via in-depth interviews and/or observations.', 'timeFrame': 'Up to 10 years follow-up after screening period'}, {'measure': 'Effectiveness of the atrial fibrillation screening based on incidence each individual MACE component', 'description': 'Effectiveness of the atrial fibrillation screening (the home-based screening program and follow-up strategy), based on the incidence of each individual component defining MACE (for the atrial fibrillation screening defined as cardiovascular mortality, non-hemorrhagic stroke, and myocardial infarction, including CABG and PCI).\n\nThis will be evaluated by comparing the event rates in the intervention group (the sample of 160,000 subjects invited for screening) and the control group (the sample of 160,000 subjects not invited for screening).', 'timeFrame': 'Up to 10 years follow-up after screening period'}, {'measure': 'Overall effectiveness of broader population-based screening strategies applied to screening on heart failure, coronary artery disease, and type 2 diabetes.', 'description': 'Overall effectiveness of broader population-based screening strategies, focused on the detection (and potentially treatment) of heart failure, coronary artery disease, and type 2 diabetes in subjects aged 50-75 years. This will be evaluated based on participation rate, yield, and (cost-)effectiveness of the screening strategies, similarly to what is described in the previous sections, but then applied to screening on heart failure, coronary artery disease, and type 2 diabetes.', 'timeFrame': 'Up to 10 years follow-up after screening period'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* aged between 50 and 75 years\n* living in the selected regions (Breda, Utrecht, Arnhem, Eindhoven)\n\nExclusion Criteria:\n\n* age \\<50 years or \\>75 years\n* not living in the selected regions (Breda, Utrecht, Arnhem, Eindhoven)\n* being institutionalized (e.g., subjects with intellectual disabilities or subjects living in nursing homes who have a limited life expectancy)\n* participants of the previously conducted THOMAS Study (NL65228.042.18, METc 2018/687) will be excluded.', 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '50 Years', 'maximumAge': '75 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Prof. Dr. F. W. Asselbergs', 'affiliation': 'Amsterdam UMC', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Prof. Dr. R. T. Gansevoort', 'affiliation': 'UMC Groningen', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Stichting Amsterdam UMC', 'city': 'Amsterdam', 'country': 'Netherlands', 'geoPoint': {'lat': 52.37403, 'lon': 4.88969}}]}, 'referencesModule': {'references': [{'pmid': '37597522', 'type': 'BACKGROUND', 'citation': 'van Mil D, Kieneker LM, Evers-Roeten B, Thelen MHM, de Vries H, Hemmelder MH, Dorgelo A, van Etten RW, Heerspink HJL, Gansevoort RT. Participation rate and yield of two home-based screening methods to detect increased albuminuria in the general population in the Netherlands (THOMAS): a prospective, randomised, open-label implementation study. Lancet. 2023 Sep 23;402(10407):1052-1064. doi: 10.1016/S0140-6736(23)00876-0. Epub 2023 Aug 16.'}], 'seeAlsoLinks': [{'label': 'Related Info', 'url': 'https://checkathome.nl'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001281', 'term': 'Atrial Fibrillation'}, {'id': 'D051436', 'term': 'Renal Insufficiency, Chronic'}, {'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D001145', 'term': 'Arrhythmias, Cardiac'}, {'id': 'D006331', 'term': 'Heart Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D051437', 'term': 'Renal Insufficiency'}, {'id': 'D007674', 'term': 'Kidney Diseases'}, {'id': 'D014570', 'term': 'Urologic Diseases'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D002908', 'term': 'Chronic Disease'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}}",False,
"{'identificationModule': {'nctId': 'NCT03761446', 'orgStudyIdInfo': {'id': 'TRIMD 1330040'}, 'organization': {'fullName': 'AdventHealth Translational Research Institute', 'class': 'OTHER'}, 'briefTitle': 'The Role of Type 2 Diabetes on Skeletal Muscle Atrophy and Recovery Following Bed Rest in Older Adults', 'officialTitle': 'The Role of Type 2 Diabetes on Skeletal Muscle Atrophy and Recovery Following Bed Rest in Older Adults', 'acronym': 'REST'}, 'statusModule': {'statusVerifiedDate': '2025-03', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2019-03-18', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-12', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2025-12', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2018-10-30', 'studyFirstSubmitQcDate': '2018-11-30', 'studyFirstPostDateStruct': {'date': '2018-12-03', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-03-12', 'lastUpdatePostDateStruct': {'date': '2025-03-13', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'AdventHealth Translational Research Institute', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The goal of this study is to determine the impact of pre-diabetes and type 2 diabetes on muscle atrophy during a period of bed rest and recovery of muscle mass, strength, and physical function following bed rest.', 'detailedDescription': 'Older adults with type 2 diabetes experience an accelerated rate of sarcopenia, which is the deterioration in muscle mass, strength and physical performance. Periods of disuse caused by illness or hospitalization cause rapid loss of muscle mass and strength, which negatively impact physical function upon re-ambulation. The impact of type 2 diabetes on acute muscle atrophy and recovery from disuse is a critical issue that has not been investigated.\n\nThe overall objectives of this study are to employ highly innovative methods in muscle biopsy specimens in order to decipher the temporal sequence by which mitochondrial dysfunction and lipotoxicity in older adults with pre-diabetes and type 2 diabetes impact atrophy and recovery of muscle mass, strength and physical function following bed rest. Older adults with and without pre-diabetes/type 2 diabetes will complete 10 days of strict bed rest followed by 4 weeks of ambulatory recovery. During bed rest muscle biopsies will be collected to determine mitochondrial function and lipid profile. During the recovery period the recovery of muscle mass, strength and physical function will be determined.'}, 'conditionsModule': {'conditions': ['Type 2 Diabetes', 'Muscle Atrophy', 'Aging', 'Sedentary Behavior', 'Pre-diabetes']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'BASIC_SCIENCE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 50, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Older adults with pre-diabetes or type 2 Diabetes', 'type': 'EXPERIMENTAL', 'description': 'Male and female older adults between the ages 60-80 with pre-diabetes or type 2 diabetes', 'interventionNames': ['Behavioral: Bed rest']}, {'label': 'Older adults without pre-diabetes or Type 2 Diabetes', 'type': 'EXPERIMENTAL', 'description': 'Male and female older adults between the ages 60-80 without pre-diabetes or type 2 diabetes', 'interventionNames': ['Behavioral: Bed rest']}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'Bed rest', 'description': 'The participant will remain in bed rest for 10 complete days.', 'armGroupLabels': ['Older adults with pre-diabetes or type 2 Diabetes', 'Older adults without pre-diabetes or Type 2 Diabetes']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Leg Lean Mass', 'description': 'Determined by DXA (dual energy x-ray absorptiometry)', 'timeFrame': 'Pre and Post Bed Rest and following 4 weeks of ambulatory recovery'}, {'measure': 'Mitochondrial Respiration', 'description': 'Determined by high resolution respirometry in permeabilized muscle fiber bundles', 'timeFrame': 'Pre and Post Bed Rest'}], 'secondaryOutcomes': [{'measure': 'Insulin Sensitivity', 'description': 'Determined by hyperinsulinemic euglycemic glucose clamp', 'timeFrame': 'Pre and Post Bed Rest'}, {'measure': 'Physical function', 'description': 'Determined by short physical performance battery', 'timeFrame': 'Pre and Post Bed Rest'}]}, 'eligibilityModule': {'eligibilityCriteria': ""Inclusion Criteria\n\n1. Participant must be male or female between the ages of 60 and 80 years of age.\n2. Participant has pre-diabetes or type 2 diabetes and is only taking DPP-4 inhibitors, Sulfonylureas and/or Metformin therapy (but not Insulin, injectable incretin mimeticsSGL2 inhibitors, and Thiazolidinedione's), and has an A1C \\< 8.0.\n\n   1. Pre-Diabetics are defined as having an HgbA1c of greater than or equal to 5.7% and less 6.5%, or a fasting glucose of greater than or equal to 100 mg/dl and less than 126 mg/dl or has a glucose of greater than or equal to 140 mg/dl and less than 200mg/dl at the 2 hour blood draw during OGTT\n   2. The non-diabetic control group is defined as having an HgbA1c of less than 5.7%, a fasting glucose of less than 100 mg/dl and a glucose level less than 140 mg/dl at the 2hr blood draw during the OGTT.\n3. Participant must have renal function with an estimated glomerular filtration rate (eGFR) \\> 45 ml/min/1.73m2 determined at screening.\n4. Participant's triglyceride level is \\< 350 mg/dl and LDL cholesterol is ≤ 150 mg/dl at screening.\n5. Participants must be non-smokers. Non-smokers as defined by not smoking any tobacco or using nicotine-containing products and not using vape pens or vaporizers within 3 months prior to screening.\n6. Participant states willingness to follow protocol as described, including consumption of study product per protocol, the prescribed activity level and completing any forms needed throughout the study.\n7. Participant has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board/Independent Ethics Committee, and provided Health Insurance Portability and Accountability Act authorization (HIPAA) or other privacy authorization prior to any participation in study.\n\nExclusion Criteria\n\n1. Participant has type 1 Diabetes.\n2. BMI \\> 40.0 kg/m2\n3. Participant is actively pursuing weight loss and/or lifestyle changes.\n4. Participant has a history of pressure ulcers.\n5. Participant has a stated history of Deep Vein Thrombosis (DVT), pulmonary embolism, or a known hypercoagulable condition, or other clotting or bleeding disorders.\n6. History of gastrointestinal or intracranial hemorrhage.\n7. History of stroke or cerebrovascular accident.\n8. Recent history of major trauma (within 3 months).\n9. Thrombocytopenia (of any cause) or hyperkalemia (K \\> 5.0) on screening laboratory assay. May repeat lab value per PI discretion.\n10. Untreated or poorly controlled hypertension (SBP \\> 150, DBP \\> 95), or hypotension (SBP \\<100 DBP \\<60)\n11. Participant has a TSH greater than or equal to 10mIU/L.\n12. Participant has current infection (requiring prescription antimicrobial or antiviral medication, or hospitalization), or corticosteroid treatment (with the exception of inhaled or topical steroids) in the last 3 months prior to screening visit.\n13. Participant is currently taking anti-inflammatory medication or has anti-inflammatory medication in the 1 weeks prior to screening (including over the counter formulations; e.g. Aleve, Motrin, ibuprofen, naproxen).\n14. Participant has had surgery requiring \\> 2 days of hospitalization in the last 1 month prior to screening visit.\n15. Participant has an active malignancy or autoimmune disease.\n16. Participant has current significantly impaired liver function in the opinion of the study PI (mild asymptomatic fatty liver is acceptable), or hepatic enzyme tests are ≥ 2.5 times normal limit.\n17. Participant has a chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV.\n18. Participant is an amputee and/or has presence of partial or full artificial limb.\n19. Participant has had a significant cardiovascular event (e.g. myocardial infarction, stroke) ≤ 6 months prior to screening visit; or stated history of congestive heart failure; or participant has evidence of cardiovascular disease assessed during the ECG at screening. In the event of a positive stress test, participants are referred to their primary care physician. If the electrocardiogram (ECG) is determined to be a false positive, participant may be allowed to participate in study after confirmatory records obtained.\n20. Participant has a history of, or currently has uncontrolled severe diarrhea, nausea or vomiting.\n21. Participant has an obstruction of the gastrointestinal tract, inflammatory bowel disease, short bowel syndrome or other forms of gastrointestinal disease such as stage III or above gastroesophageal reflux disease, gastroparesis, peptic ulcer disease, celiac disease, intestinal dysmotility, diverticulitis, ischemic colitis and bariatric surgery.\n22. Participant cannot abstain from alcohol for the pre bed rest and bed rest portion of the study. For the recovery portion of the study the participant must agree to consume no more than 1 glass of wine (4-5 oz) or bottle of beer (12 oz) /day.\n23. Participant cannot refrain from taking medications/dietary supplements/herbals or substances that could modulate glucose metabolism (other than oral hypoglycemic medications), or are considered anabolic, or reduce weight (fat mass), or that may interact with low-molecular weight heparin or induce hypo- or hyper-coagulable state, in the opinion of the PI or medical provider, starting one week prior to enrollment and over the entire course of the study. These include progestational agents (except prescribed birth control), steroids, growth hormone, dronabinol, marijuana, calcium-beta-hydroxy-betamethylbutyrate (CaHMB), free amino acid supplements and dietary supplements to aid weight loss.\n24. Participant has a mini-Mental State Examination score \\< 21.\n25. Subjects who fulfill any of the contraindications for MRI; examples include metal implants, devices, paramagnetic objects contained within the body and excessive or metal-containing tattoos.\n26. Unable to participate in MR or DEXA assessments due to physical limitations of equipment tolerances (e.g., MRI bore size and DEXA 450-pound weight limit) claustrophobia, or based on Investigator's judgment at screening.\n27. Participant has a sensitivity or allergy to lidocaine.\n28. Participant has a sensitivity or allergy to heparin, enoxaparin, or other low molecular weight heparin.\n29. History of allergy to pork products or any component of the formulation of low-molecular weight heparin for dosing.\n30. History of heparin induced thrombocytopenia.\n31. Hemoglobin \\< 10.0 g/dL for females; \\< 11.0 g/dL for males; or participant has clinically significant signs/symptoms of anemia in the opinion of the PI or medical provider.\n32. Concomitant medications with known contraindication or interaction with low-molecular weight heparin (including anti-platelet agents, anti-coagulant agents, non-steroidal anti-inflammatory drugs)\n33. Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete the study.\n34. Participant experiences symptoms of claudication. Symptoms include cramping pain in the legs and/or difficulty walking."", 'healthyVolunteers': True, 'sex': 'ALL', 'minimumAge': '60 Years', 'maximumAge': '80 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Recruitment Department', 'role': 'CONTACT', 'phone': '407-303-7100', 'email': 'tri@flhosp.org'}], 'overallOfficials': [{'name': 'Paul Coen, PhD', 'affiliation': 'Translational Research Institute for Metabolism and Diabetes', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Translational Research Institute for Metabolism and Diabetes', 'status': 'RECRUITING', 'city': 'Orlando', 'state': 'Florida', 'zip': '32804', 'country': 'United States', 'contacts': [{'name': 'Recruitment Department', 'role': 'CONTACT', 'phone': '407-303-7100', 'email': 'tri@flhosp.org'}], 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}, {'id': 'D009133', 'term': 'Muscular Atrophy'}, {'id': 'D057185', 'term': 'Sedentary Behavior'}, {'id': 'D018149', 'term': 'Glucose Intolerance'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D020879', 'term': 'Neuromuscular Manifestations'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D001284', 'term': 'Atrophy'}, {'id': 'D020763', 'term': 'Pathological Conditions, Anatomical'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D001519', 'term': 'Behavior'}, {'id': 'D006943', 'term': 'Hyperglycemia'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D001510', 'term': 'Bed Rest'}], 'ancestors': [{'id': 'D013812', 'term': 'Therapeutics'}]}}",False,
"{'identificationModule': {'nctId': 'NCT06575868', 'orgStudyIdInfo': {'id': 'STUDY00005304'}, 'organization': {'fullName': 'Tufts Medical Center', 'class': 'OTHER'}, 'briefTitle': 'Myo-inositol During Pregnancy to Prevent Gestational Diabetes', 'officialTitle': 'Continuous Glucose Monitoring in Myo-inositol Supplemented Obese Pregnant Individuals: a Feasibility Pilot Randomized Control Trial'}, 'statusModule': {'statusVerifiedDate': '2025-04', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-03-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-12-31', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2027-06-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-08-26', 'studyFirstSubmitQcDate': '2024-08-26', 'studyFirstPostDateStruct': {'date': '2024-08-28', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-04-24', 'lastUpdatePostDateStruct': {'date': '2025-04-29', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Tufts Medical Center', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'Myoinositol is an insulin-like compound that is present in both plant and animal cells. Humans synthesize it naturally, but it is also obtained in our diet. It works through an intracellular signaling pathway to increase insulin sensitivity. Myoinositol has been used as an over-the-counter (OTC) supplement in the management of polycystic ovarian syndrome due to this effect. Myoinositol has also been shown to improve glycemic profiles in pregnant euglycemic women and well as improve insulin sensitivity in pregnant patients with gestational diabetes mellitus (GDM).\n\nThis is a double blind RCT offering myo-inositol or placebo to those who are eligible and enrolled.'}, 'conditionsModule': {'conditions': ['Pregnancy Related']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Myo-inositol', 'type': 'EXPERIMENTAL', 'interventionNames': ['Dietary Supplement: Myo-inositol']}, {'label': 'Placebo myo-inositol', 'type': 'PLACEBO_COMPARATOR', 'interventionNames': ['Dietary Supplement: Myo-inositol placebo']}], 'interventions': [{'type': 'DIETARY_SUPPLEMENT', 'name': 'Myo-inositol', 'description': 'Patients would begin taking myoinositol upon recruitment', 'armGroupLabels': ['Myo-inositol']}, {'type': 'DIETARY_SUPPLEMENT', 'name': 'Myo-inositol placebo', 'description': 'Patients would begin taking placebo upon recruitment', 'armGroupLabels': ['Placebo myo-inositol']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Eligibility', 'description': 'proportion of screened women who were eligible', 'timeFrame': '1 year'}, {'measure': 'Glucose levels', 'description': 'Average glucose levels during CGM monitoring period for those enrolled', 'timeFrame': '1 year'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\nSingleton gestations\n\nWomen aged \\> 18 years and \\< 45 years\n\nRecruited before 16 weeks gestation\n\nObese (pre-pregnancy BMI ≥ 30)\n\nReceiving prenatal care at Tufts Medical Center\n\nPlanning to give birth at Tufts Medical Center\n\nCan tolerate glucose tolerance test\n\nWilling and able to wear CGM\n\nWilling and able to sign informed consent\n\nExclusion Criteria:\n\nMultiple gestation\n\nPreexisting diabetes\n\nTaking medications that impact body weight or metabolism (eg metformin)\n\nInability to tolerate glucose tolerance test\n\nAdults unable to consent (cognitively impaired adults)\n\nWards of the state\n\nNon-viable neonates\n\nNeonates of uncertain viability', 'healthyVolunteers': False, 'sex': 'FEMALE', 'minimumAge': '18 Years', 'maximumAge': '45 Years', 'stdAges': ['ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Zeinab Kassem, MD', 'role': 'CONTACT', 'phone': '617-636-9897', 'email': 'zeinab.kassem@tuftsmedicine.org'}], 'locations': [{'facility': 'Tufts Medical Center', 'status': 'RECRUITING', 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02111', 'country': 'United States', 'contacts': [{'name': 'Zeunab Kassem', 'role': 'CONTACT', 'phone': '617-636-9897', 'email': 'zeinab.kassem@tuftsmedicalcenter.org'}], 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}]}, 'referencesModule': {'references': [{'pmid': '9231801', 'type': 'BACKGROUND', 'citation': 'Muller G, Wied S, Crecelius A, Kessler A, Eckel J. Phosphoinositolglycan-peptides from yeast potently induce metabolic insulin actions in isolated rat adipocytes, cardiomyocytes, and diaphragms. Endocrinology. 1997 Aug;138(8):3459-75. doi: 10.1210/endo.138.8.5308.'}, {'pmid': '23764390', 'type': 'BACKGROUND', 'citation': 'Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013 Oct;95(10):1811-27. doi: 10.1016/j.biochi.2013.05.011. Epub 2013 Jun 10.'}, {'pmid': '23336594', 'type': 'BACKGROUND', 'citation': 'Artini PG, Di Berardino OM, Papini F, Genazzani AD, Simi G, Ruggiero M, Cela V. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol. 2013 Apr;29(4):375-9. doi: 10.3109/09513590.2012.743020. Epub 2013 Jan 22.'}, {'pmid': '17664885', 'type': 'BACKGROUND', 'citation': 'Scioscia M, Kunjara S, Gumaa K, Gomez Galan AM, McLean P, Rodeck CH, Rademacher TW. Altered urinary release of inositol phosphoglycan A-type in women with gestational diabetes mellitus. Gynecol Obstet Invest. 2007;64(4):217-23. doi: 10.1159/000106494. Epub 2007 Jul 30.'}, {'pmid': '24488919', 'type': 'BACKGROUND', 'citation': 'Malvasi A, Casciaro F, Minervini MM, Kosmas I, Mynbaev OA, Pacella E, Monti Condesnitt V, Creanza A, Di Renzo GC, Tinelli A. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. Eur Rev Med Pharmacol Sci. 2014;18(2):270-4.'}, {'pmid': '21414183', 'type': 'BACKGROUND', 'citation': ""Corrado F, D'Anna R, Di Vieste G, Giordano D, Pintaudi B, Santamaria A, Di Benedetto A. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet Med. 2011 Aug;28(8):972-5. doi: 10.1111/j.1464-5491.2011.03284.x.""}, {'pmid': '26241420', 'type': 'BACKGROUND', 'citation': ""D'Anna R, Di Benedetto A, Scilipoti A, Santamaria A, Interdonato ML, Petrella E, Neri I, Pintaudi B, Corrado F, Facchinetti F. Myo-inositol Supplementation for Prevention of Gestational Diabetes in Obese Pregnant Women: A Randomized Controlled Trial. Obstet Gynecol. 2015 Aug;126(2):310-315. doi: 10.1097/AOG.0000000000000958.""}, {'pmid': '29774465', 'type': 'BACKGROUND', 'citation': 'Fraticelli F, Celentano C, Zecca IA, Di Vieste G, Pintaudi B, Liberati M, Franzago M, Di Nicola M, Vitacolonna E. Effect of inositol stereoisomers at different dosages in gestational diabetes: an open-label, parallel, randomized controlled trial. Acta Diabetol. 2018 Aug;55(8):805-812. doi: 10.1007/s00592-018-1157-4. Epub 2018 May 17.'}, {'pmid': '33893377', 'type': 'BACKGROUND', 'citation': ""D'Anna R, Corrado F, Loddo S, Gullo G, Giunta L, Di Benedetto A. Myoinositol plus alpha-lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study. Sci Rep. 2021 Apr 23;11(1):8866. doi: 10.1038/s41598-021-88329-x.""}, {'pmid': '33238798', 'type': 'BACKGROUND', 'citation': ""Vitale SG, Corrado F, Caruso S, Di Benedetto A, Giunta L, Cianci A, D'Anna R. Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes - a randomized and open-label, placebo-controlled clinical trial. Int J Food Sci Nutr. 2021 Aug;72(5):670-679. doi: 10.1080/09637486.2020.1852191. Epub 2020 Nov 25.""}, {'pmid': '28325784', 'type': 'BACKGROUND', 'citation': 'Farren M, Daly N, McKeating A, Kinsley B, Turner MJ, Daly S. The Prevention of Gestational Diabetes Mellitus With Antenatal Oral Inositol Supplementation: A Randomized Controlled Trial. Diabetes Care. 2017 Jun;40(6):759-763. doi: 10.2337/dc16-2449. Epub 2017 Mar 21.'}, {'pmid': '33721623', 'type': 'BACKGROUND', 'citation': 'Kulshrestha V, Balani S, Kachhawa G, Vanamail P, Kumari R, Sharma JB, Bhatla N. Efficacy of myoinositol in treatment of gestational diabetes mellitus in Asian Indian women: A pilot randomized clinical trial. Eur J Obstet Gynecol Reprod Biol. 2021 May;260:42-47. doi: 10.1016/j.ejogrb.2021.02.017. Epub 2021 Feb 19.'}, {'pmid': '35277398', 'type': 'BACKGROUND', 'citation': 'Amaefule CE, Drymoussi Z, Gonzalez Carreras FJ, Pardo Llorente MDC, Lanz D, Dodds J, Sweeney L, Pizzo E, Thomas A, Heighway J, Daru J, Sobhy S, Poston L, Khalil A, Myers J, Harden A, Hitman G, Khan KS, Zamora J, Perez T, Huda MSB, Thangaratinam S. Myo-inositol nutritional supplement for prevention of gestational diabetes (EMmY): a randomised, placebo-controlled, double-blind pilot trial with nested qualitative study. BMJ Open. 2022 Mar 11;12(3):e050110. doi: 10.1136/bmjopen-2021-050110.'}, {'pmid': '37769316', 'type': 'BACKGROUND', 'citation': 'Horgan R, Hage Diab Y, Fishel Bartal M, Sibai BM, Saade G. Continuous Glucose Monitoring in Pregnancy. Obstet Gynecol. 2024 Feb 1;143(2):195-203. doi: 10.1097/AOG.0000000000005374. Epub 2023 Sep 28.'}, {'pmid': '34564868', 'type': 'BACKGROUND', 'citation': 'Garcia-Moreno RM, Benitez-Valderrama P, Barquiel B, Gonzalez Perez-de-Villar N, Hillman N, Lora Pablos D, Herranz L. Efficacy of continuous glucose monitoring on maternal and neonatal outcomes in gestational diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials. Diabet Med. 2022 Jan;39(1):e14703. doi: 10.1111/dme.14703. Epub 2021 Oct 13.'}, {'pmid': '26698911', 'type': 'BACKGROUND', 'citation': ""Santamaria A, Di Benedetto A, Petrella E, Pintaudi B, Corrado F, D'Anna R, Neri I, Facchinetti F. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. J Matern Fetal Neonatal Med. 2016 Oct;29(19):3234-7. doi: 10.3109/14767058.2015.1121478. Epub 2015 Dec 23.""}, {'pmid': '30338829', 'type': 'BACKGROUND', 'citation': ""Pintaudi B, Di Vieste G, Corrado F, Lucisano G, Giunta L, D'Anna R, Di Benedetto A. Effects of myo-inositol on glucose variability in women with gestational diabetes. Eur Rev Med Pharmacol Sci. 2018 Oct;22(19):6567-6572. doi: 10.26355/eurrev_201810_16073.""}, {'pmid': '23340885', 'type': 'BACKGROUND', 'citation': ""D'Anna R, Scilipoti A, Giordano D, Caruso C, Cannata ML, Interdonato ML, Corrado F, Di Benedetto A. myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care. 2013 Apr;36(4):854-7. doi: 10.2337/dc12-1371. Epub 2013 Jan 22.""}, {'pmid': '37909353', 'type': 'BACKGROUND', 'citation': 'Parker ED, Lin J, Mahoney T, Ume N, Yang G, Gabbay RA, ElSayed NA, Bannuru RR. Economic Costs of Diabetes in the U.S. in 2022. Diabetes Care. 2024 Jan 1;47(1):26-43. doi: 10.2337/dci23-0085.'}, {'pmid': '21327952', 'type': 'BACKGROUND', 'citation': 'Baptiste-Roberts K, Nicholson WK, Wang NY, Brancati FL. Gestational diabetes and subsequent growth patterns of offspring: the National Collaborative Perinatal Project. Matern Child Health J. 2012 Jan;16(1):125-32. doi: 10.1007/s10995-011-0756-2.'}, {'pmid': '10219066', 'type': 'BACKGROUND', 'citation': 'Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999 Apr 29;340(17):1314-20. doi: 10.1056/NEJM199904293401703.'}, {'pmid': '22122627', 'type': 'BACKGROUND', 'citation': ""D'Anna R, Di Benedetto V, Rizzo P, Raffone E, Interdonato ML, Corrado F, Di Benedetto A. Myo-inositol may prevent gestational diabetes in PCOS women. Gynecol Endocrinol. 2012 Jun;28(6):440-2. doi: 10.3109/09513590.2011.633665. Epub 2011 Nov 28.""}, {'pmid': '22296306', 'type': 'BACKGROUND', 'citation': 'Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012 Jul;28(7):509-15. doi: 10.3109/09513590.2011.650660. Epub 2012 Feb 1.'}, {'pmid': '23327487', 'type': 'BACKGROUND', 'citation': ""Matarrelli B, Vitacolonna E, D'Angelo M, Pavone G, Mattei PA, Liberati M, Celentano C. Effect of dietary myo-inositol supplementation in pregnancy on the incidence of maternal gestational diabetes mellitus and fetal outcomes: a randomized controlled trial. J Matern Fetal Neonatal Med. 2013 Jul;26(10):967-72. doi: 10.3109/14767058.2013.766691. Epub 2013 Mar 1.""}, {'pmid': '30558466', 'type': 'BACKGROUND', 'citation': 'Celentano C, Matarrelli B, Pavone G, Vitacolonna E, Mattei PA, Berghella V, Liberati M. The influence of different inositol stereoisomers supplementation in pregnancy on maternal gestational diabetes mellitus and fetal outcomes in high-risk patients: a randomized controlled trial. J Matern Fetal Neonatal Med. 2020 Mar;33(5):743-751. doi: 10.1080/14767058.2018.1500545. Epub 2018 Dec 17.'}, {'pmid': '35686634', 'type': 'BACKGROUND', 'citation': 'Esmaeilzadeh S, Ghadimi R, Mashayekh-Amiri S, Delavar MA, Basirat Z. The effect of myo-inositol supplementation on the prevention of gestational diabetes in overweight pregnant women: a randomized, double-blind, controlled trial. Minerva Obstet Gynecol. 2023 Aug;75(4):357-364. doi: 10.23736/S2724-606X.22.05036-9. Epub 2022 Jun 8.'}, {'pmid': '32324061', 'type': 'BACKGROUND', 'citation': ""Castorino K, Polsky S, O'Malley G, Levister C, Nelson K, Farfan C, Brackett S, Puhr S, Levy CJ. Performance of the Dexcom G6 Continuous Glucose Monitoring System in Pregnant Women with Diabetes. Diabetes Technol Ther. 2020 Dec;22(12):943-947. doi: 10.1089/dia.2020.0085.""}, {'pmid': '36790138', 'type': 'BACKGROUND', 'citation': 'Motuhifonua SK, Lin L, Alsweiler J, Crawford TJ, Crowther CA. Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes. Cochrane Database Syst Rev. 2023 Feb 15;2(2):CD011507. doi: 10.1002/14651858.CD011507.pub3.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'interventionBrowseModule': {'meshes': [{'id': 'D007294', 'term': 'Inositol'}], 'ancestors': [{'id': 'D013402', 'term': 'Sugar Alcohols'}, {'id': 'D000438', 'term': 'Alcohols'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D002241', 'term': 'Carbohydrates'}]}}",False,
"{'identificationModule': {'nctId': 'NCT06784674', 'orgStudyIdInfo': {'id': 'STUDY00005491'}, 'organization': {'fullName': 'University of Texas at Austin', 'class': 'OTHER'}, 'briefTitle': 'Maternal Abdominal Morphology Assessment', 'officialTitle': 'Diabetes Prediction During Pregnancy Using Pancreas MRI', 'acronym': 'MAMA'}, 'statusModule': {'statusVerifiedDate': '2025-10', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-05-06', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2030-12', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2031-12', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2025-01-14', 'studyFirstSubmitQcDate': '2025-01-14', 'studyFirstPostDateStruct': {'date': '2025-01-20', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-10-20', 'lastUpdatePostDateStruct': {'date': '2025-10-22', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'John Virostko', 'investigatorTitle': 'John Virostko, Associate Professor, Department of Diagnostic Medicine', 'investigatorAffiliation': 'University of Texas at Austin'}, 'leadSponsor': {'name': 'University of Texas at Austin', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Institutes of Health (NIH)', 'class': 'NIH'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'Previous studies have shown that pancreas size tends to be smaller in individuals with diabetes compared to those without diabetes. The investigators have recently found that pancreas size increases during pregnancy. The MAMA study aims to examine changes in the pancreas that occur during pregnancy, in both pregnant mothers and their babies, and find out how they are affected by maternal diabetes.\n\nThe MAMA study is a prospective cohort study that will follow women and their babies through pregnancy and one year postpartum. Women aged 18-54, who are under 14 weeks pregnant are being recruited to participate in the MAMA study.', 'detailedDescription': ""As pancreas size is thought to reflect pancreatic insulin production and/or islet mass, monitoring pancreas size during and after pregnancy may advance the investigators' understanding of gestational diabetes mellitus (GDM) incidence and progression. Information on pancreas size changes during pregnancy, typical fetal pancreatic development, the relationship between pancreas size and GDM risk, and the relationship between pancreas size and neonatal hypoglycemia are largely unknown. Through this project, magnetic resonance imaging (MRI) will be used to measure changes in pancreas size during pregnancy and the effect of maternal diabetes on these measures.\n\nThis prospective cohort study is observational and will include up to 87 pregnant women who are between 18-54 years old. Study visits will take place at approximately 15-18 weeks gestation, 24-28 weeks gestation, 34-38 weeks gestation, and 1 year-1 year and 2 months postpartum. At each study visit, participants will self-report their height and weight, have their blood pressure measured, have their blood drawn, have an HbA1c finger stick test, participate in oral glucose tolerance testing (OGTT), complete an MRI scan, and undergo continuous glucose monitoring (CGM).""}, 'conditionsModule': {'conditions': ['Pregnancy Related', 'Infant Development', 'Pancreas', 'Diabetes'], 'keywords': ['Pregnancy', 'Pancreas', 'Diabetes']}, 'designModule': {'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Maternal blood samples will be collected at study visits.'}, 'enrollmentInfo': {'count': 87, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'MAMA Study Participants', 'description': 'Approximately 87 pregnant women, aged 18-54, living in the Greater Austin area, will participate in the MAMA study. The MAMA study is an observational study.', 'interventionNames': ['Other: No intervention']}], 'interventions': [{'type': 'OTHER', 'name': 'No intervention', 'description': 'Observational study', 'armGroupLabels': ['MAMA Study Participants']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Maternal Pancreatic Volume', 'description': 'Maternal pancreatic volume will be measured at each study visit. MRI will be utilized to determine maternal pancreatic volume in cm\\^3.', 'timeFrame': '15-18 weeks gestation, 24-28 weeks gestation, and 34-38 weeks gestation as well as 1 year-1 year and 2 months postpartum.'}, {'measure': 'Fetal Pancreatic Volume', 'description': 'Fetal pancreatic volume will be measured at each study visit. MRI will be utilized to determine fetal pancreatic volume in utero in cm\\^3. Fetal pancreatic volume will not be ascertained at the final study visit.', 'timeFrame': '15-18 weeks gestation, 24-28 weeks gestation, and 34-38 weeks gestation.'}], 'secondaryOutcomes': [{'measure': 'Plasma Insulin', 'description': 'Plasma Insulin values (µU/mL or pmol/L) measured via blood draw will be utilized to calculate Glycemic Control and Insulin Sensitivity.', 'timeFrame': '15-18 weeks gestation, 24-28 weeks gestation, and 34-38 weeks gestation as well as 1 year-1 year and 2 months postpartum.'}, {'measure': 'Plasma Glucose', 'description': 'Plasma Insulin values (mg/dL or mmol/L) measured via blood draw will be utilized to calculate Glycemic Control and Insulin Sensitivity.', 'timeFrame': '15-18 weeks gestation, 24-28 weeks gestation, and 34-38 weeks gestation as well as 1 year-1 year and 2 months postpartum.'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* Pregnant women, with a singleton gestation\n* Age 18 - 54 years at screening\n* Gestational age \\< 14 weeks\n* Willing to commit to 1 year postpartum follow up\n* Planning to remain in geographical vicinity of Austin for 1 year after delivery\n\nExclusion Criteria:\n\n* Presence of any mechanically or magnetically activated implants\n* Claustrophobia\n* Other contraindication for MRI\n* BMI ≥ 38.0 or maximum width less than 48 cm (necessary to fit within the MRI field of view)', 'healthyVolunteers': True, 'sex': 'FEMALE', 'minimumAge': '18 Years', 'maximumAge': '54 Years', 'stdAges': ['ADULT'], 'studyPopulation': 'The investigators intend to enroll 87 total participants. The study population will consist of women who are under 14 weeks pregnant with a singleton gestation, aged 18-54, living in the Greater Austin Area.', 'samplingMethod': 'NON_PROBABILITY_SAMPLE'}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Jack Virostko, Ph.D.', 'role': 'CONTACT', 'phone': '512-495-5126', 'email': 'jack.virostko@austin.utexas.edu'}, {'name': 'Ingrid Harris, MPH', 'role': 'CONTACT', 'phone': '512-471-0999', 'email': 'ingrid.harris@austin.utexas.edu'}], 'overallOfficials': [{'name': 'Jack Virostko, Ph.D.', 'affiliation': 'University of Texas at Austin', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Dell Medical School Health Discovery Building', 'status': 'RECRUITING', 'city': 'Austin', 'state': 'Texas', 'zip': '78701', 'country': 'United States', 'contacts': [{'name': 'Ingrid Harris, MPH', 'role': 'CONTACT', 'phone': '5124710999', 'email': 'ingrid.harris@austin.utexas.edu'}], 'geoPoint': {'lat': 30.26715, 'lon': -97.74306}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}], 'ancestors': [{'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}}",False,
"{'identificationModule': {'nctId': 'NCT07186660', 'orgStudyIdInfo': {'id': '302645'}, 'secondaryIdInfos': [{'id': '3-SRA-2025-1773-M-B', 'type': 'OTHER_GRANT', 'domain': 'Breakthrough T1D'}], 'organization': {'fullName': 'University of Virginia', 'class': 'OTHER'}, 'briefTitle': 'Evaluation of a Novel Insulin Sensitizer in People With Type 1 Diabetes', 'officialTitle': 'Evaluation of a Novel Insulin Sensitizer on Glycemic Control, Insulin Usage, and Cardiovascular Biomarkers in People With Type 1 Diabetes Who Use Closed-loop Automated Insulin Delivery', 'acronym': 'WBH003'}, 'statusModule': {'statusVerifiedDate': '2025-09', 'overallStatus': 'NOT_YET_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-10-15', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2028-09', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2028-09', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2025-09-12', 'studyFirstSubmitQcDate': '2025-09-18', 'studyFirstPostDateStruct': {'date': '2025-09-22', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-09-22', 'lastUpdatePostDateStruct': {'date': '2025-09-26', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'William Horton, MD', 'investigatorTitle': 'Associate Professor', 'investigatorAffiliation': 'University of Virginia'}, 'leadSponsor': {'name': 'University of Virginia', 'class': 'OTHER'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to see if the study drug CIR-0602K will improve glucose time-in-range and/or lower total daily insulin dose in people with type 1 diabetes who are using closed-loop automated insulin delivery. Researchers will compare CIR-0602K to a placebo (a look-alike substance that contains no drug) to see if it achieves the investigational endpoints. If the study results show that the drug works to increase time-in-range and lower insulin doses, this will lead to further studies which may then make the drug available to the public.', 'detailedDescription': 'Participants in the study will:\n\n* Come to the Clinical Research Unit (CRU) at UVA Medical Center for 3 visits: Screening, Baseline (Admission 1) and End-of-Study (Admission 2).\n* Complete various tests of cardiovascular health at each visit.\n* Take either an experimental drug (CIR-0602K) or placebo for 12 weeks.\n* Wear a study CGM with their personal insulin pump for 12 weeks.\n* Be given a ketone meter and strips and be asked to take a fingerstick ketone reading every morning for 12 weeks.\n* The study team will contact the participants regularly during the study to check their health and how they are tolerating the study drug/placebo.\n* Return the study CGM, ketone meter, and remaining supplies, etc. at the end of the study.\n* Notify the study team of any illness, injury, hypoglycemic or hyperglycemic events during the study'}, 'conditionsModule': {'conditions': ['Type 1 Diabetes (T1D)', 'Glycemic Control for Diabetes Mellitus', 'Insulin', 'Ketones', 'Cardiovascular Health'], 'keywords': ['Type 1 Diabetes', 'closed loop technology', 'time-in-range', 'adjunct therapy', 'cardiovascular health']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'maskingDescription': 'Clinical research team', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 40, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'CIR-0602K', 'type': 'ACTIVE_COMPARATOR', 'description': 'CIR-0602K 250 mg daily', 'interventionNames': ['Drug: CIR-0602K']}, {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Matching Placebo Tablet', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'type': 'DRUG', 'name': 'CIR-0602K', 'description': 'mitochondrial pyruvate carrier inhibitor', 'armGroupLabels': ['CIR-0602K']}, {'type': 'DRUG', 'name': 'Placebo', 'description': 'Placebo tablet', 'armGroupLabels': ['Placebo']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Glucose Time-in-Range', 'description': 'Glucose time 70-180 mg/dL', 'timeFrame': '12 weeks'}], 'secondaryOutcomes': [{'measure': 'Total Daily Insulin Dose', 'description': 'Units of insulin per day', 'timeFrame': '12 weeks'}, {'measure': 'Glucose Time-above-Range', 'description': 'Glucose time \\>180 mg/dL', 'timeFrame': '12 weeks'}, {'measure': 'Glucose Time-Below-Range', 'description': 'Glucose time \\<70 mg/dL', 'timeFrame': '12 weeks'}, {'measure': 'Hemoglobin A1c', 'description': 'measure of glycemic control', 'timeFrame': '12 weeks'}, {'measure': 'Insulin Sensitivity', 'description': 'M-value from euglycemic insulin clamp', 'timeFrame': '12 weeks'}], 'otherOutcomes': [{'measure': 'Brachial Artery Flow-Mediated Dilation', 'description': 'Noninvasive measurement of blood vessel function', 'timeFrame': '12 weeks'}, {'measure': 'Carotid-Femoral Pulse Wave Velocity', 'description': 'Noninvasive measure of aortic stiffness', 'timeFrame': '12 weeks'}, {'measure': 'Radial Artery Augmentation Index', 'description': 'Noninvasive measure of radial artery stiffness', 'timeFrame': '12 weeks'}, {'measure': 'C-peptide', 'description': 'Blood test that measures endogenous insulin secretion', 'timeFrame': '12 weeks'}, {'measure': 'Daily fasting ketone level', 'description': 'Measure of blood ketone level collected by fingerstick meter conducted at home each morning', 'timeFrame': '12 weeks'}, {'measure': 'Cardiovascular Biomarkers', 'description': 'IL-6, TNF-alpha, hsCRP, E-selectin, ICAM-1, adiponectin', 'timeFrame': '12 weeks'}, {'measure': 'Peripheral Blood Mononuclear Cells', 'description': 'CD14++CD16-', 'timeFrame': '12 weeks'}]}, 'eligibilityModule': {'eligibilityCriteria': ""Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. History of type 1 diabetes for at least one year\n4. Age 18-45 years\n5. HbA1c \\<10%\n\n   * BMI 18-35 kg/m2. Within this criterion, participants must have either BMI ≥25 or total daily insulin dose of ≥0.5 units/kg/day.\n   * Currently utilizing closed-loop AID therapy that is compatible with Dexcom G7 CGM.\n   * On stable regimen of non-diabetic medications for the last 6 months.\n   * All screening labs within normal limits or not clinically significant.\n   * Ability to take oral medication and be willing to adhere to the study drug/placebo for 12 weeks.\n   * For females and males of reproductive potential: agreement to use adequate contraception during study participation and for an additional 2 weeks after the end of CIR-0602K administration.\n   * For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner during study intervention.\n   * Agreement to adhere to Lifestyle Considerations throughout study duration.\n\nExclusion Criteria:\n\n* Current Pregnancy or currently breastfeeding.\n* History of smoking tobacco products within the last two years.\n* History of alcohol abuse or illicit drug abuse within 6 months of screening.\n* Known history of human immunodeficiency virus (HIV).\n* History of other significant disease (e.g., cardiac, cerebrovascular, gastrointestinal, liver, renal, or endocrine) that could, in the investigator's view, alter study outcomes\n* Any surgical or medical condition which may significantly alter the absorption of the study drug including but not limited to the following: history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, bowel resection, gastric bypass, gastric stapling, or gastric banding, currently active inflammatory bowel syndrome.\n* Current use of any antihyperglycemic medication beyond insulin (i.e., GLP-1 receptor agonists, SGLT2 inhibitors, etc.).\n* Unstable doses (i.e., dose change within the last 4 months) of vasoactive medications (e.g., calcium-channel blockers, statins, angiotensin-converting enzyme inhibitors, diuretics, nitrates, alpha-blockers, beta-blockers, etc.).\n* Daily use of anti-inflammatory medications (e.g., ibuprofen, aspirin, prednisone, dexamethasone, etc.).\n* Diagnosis of peripheral neuropathy (assessed by screening monofilament exam).\n* Macroalbuminuria (i.e., urine albumin: creatinine \\>300 mg per g).\n* Retinopathy beyond mild, nonproliferative retinopathy.\n* History of Level 3 hypoglycemia within the last 12 months.\n* History of diabetic ketoacidosis (DKA) within the last 12 months.\n* Screening electrocardiogram (ECG) findings indicative of arrhythmia, sinus node disease, or ischemic heart disease.\n* Screening oxygen saturation \\<90%\n* History of hypersensitivity or prior adverse reaction to the study drug, closely-related compounds, or any of the stated ingredients.\n* Use of concomitant medications with a known significant metabolism by CYP2C8 or CYP2C (including paclitaxel, phenytoin, warfarin, celecoxib, tolbutamide, or repaglinide) for the duration of the study.\n* Participation in an investigational study (other than a non-treatment registry study) or received an investigational drug withing 30 days or 5 half-lives (whichever is longer) prior to randomization."", 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '45 Years', 'stdAges': ['ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Lee Hartline, MEd', 'role': 'CONTACT', 'phone': '14349245247', 'email': 'LMH9D@VIRGINIA.EDU'}], 'overallOfficials': [{'name': 'William B. Horton, MD', 'affiliation': 'University of Virginia', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'University of Virginia', 'city': 'Charlottesville', 'state': 'Virginia', 'zip': '22908', 'country': 'United States', 'contacts': [{'name': 'Horton B Horton, MD', 'role': 'CONTACT', 'phone': '(434) 924-1828', 'email': 'WBH2N@VIRGINIA.EDU'}], 'geoPoint': {'lat': 38.02931, 'lon': -78.47668}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'UNDECIDED', 'description': 'The investigative team will finalize the decision (as to whether or not to share IPD) at a later date. Of note, IPD in this study qualifies as protected health information and would thus require safety considerations.'}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}, {'id': 'D007333', 'term': 'Insulin Resistance'}, {'id': 'D007662', 'term': 'Ketosis'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D006946', 'term': 'Hyperinsulinism'}, {'id': 'D000138', 'term': 'Acidosis'}, {'id': 'D000137', 'term': 'Acid-Base Imbalance'}]}}",False,
"{'identificationModule': {'nctId': 'NCT06897982', 'orgStudyIdInfo': {'id': 'STUDY00004061'}, 'secondaryIdInfos': [{'id': '7K23DK129828-03', 'type': 'NIH', 'link': 'https://reporter.nih.gov/quickSearch/7K23DK129828-03'}], 'organization': {'fullName': 'Cedars-Sinai Medical Center', 'class': 'OTHER'}, 'briefTitle': 'Feasibility of a Nutrition Intervention for Patients With Prediabetes at a Federally Qualified Health Center', 'officialTitle': 'One-arm Feasibility and Acceptability Pilot Study of a Community-informed Nutrition Intervention to Recruit, Engage, and Retain Patients Who Are Eligible to Participate in the Diabetes Prevention Program at Two Community Health Centers in Los Angeles'}, 'statusModule': {'statusVerifiedDate': '2025-06', 'overallStatus': 'NOT_YET_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-06-30', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2027-02-28', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2027-02-28', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2025-03-13', 'studyFirstSubmitQcDate': '2025-03-20', 'studyFirstPostDateStruct': {'date': '2025-03-27', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-06-03', 'lastUpdatePostDateStruct': {'date': '2025-06-06', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Yelba Castellon-Lopez', 'investigatorTitle': 'Assistant Professor', 'investigatorAffiliation': 'Cedars-Sinai Medical Center'}, 'leadSponsor': {'name': 'Cedars-Sinai Medical Center', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)', 'class': 'NIH'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'The purpose of the study is to assess the feasibility and acceptability of incorporating hands-on nutritional demonstrations to enhance the Diabetes Prevention Program (DPP) curriculum among patients who are at-risk for prediabetes', 'detailedDescription': ""The purpose of Aim 3 is to assess the feasibility and acceptability of incorporating hands-on nutritional demonstrations to enhance the Diabetes Prevention Program (DPP) curriculum among patients who are at-risk for prediabetes. We will conduct a single arm feasibility study to collect information that will help inform a future pragmatic and fully powered RCT comparing DPP + nutritional intervention and DPP alone. Participants will be recruited from federally qualified health center community clinics with an active DPP course in session. We hypothesize that participants who undergo a 6-week nutritional intervention will not only aid DPP participation and retention but provide participants with the opportunity to apply the nutrition concepts they are actively learning in the DPP in a real-world scenario so that they can incorporate it into their daily lives. Thus, aiding in the DPP's goals of achieving at least 5% weight loss and implementing sustainable lifestyle changes with healthy eating.\n\nA total of 20 participants will be recruited from our partner federally qualified health center, safety-net community clinic sites with an existing DPP: Northeast Valley Health Corporation and AltaMed. We will recruit 2 cohorts of 10 participants each. Participants will be asked to participate in a total 6-week educational intervention using nutritional demonstrations aligned with the DPP curriculum among patients who are at-risk for prediabetes. Healthy cooking demonstrations will be led by a trained community health worker (CHW) with experience teaching about nutrition. The sessions will be co-designed by a registered dietician. Classes will be held at a community resource center with space for conducting cooking demonstrations. Classes will be held in conjunction with the existing DPP curriculum and will be offered as an opportunity to apply what is learned in the DPP curriculum. The cooking demonstrations will be in-person with a virtual option available for participants to join in if they are unable to make it to the class. This aligns with current DPP practices as participants have the option to join DPP classes in combination modality (in-person and via Zoom). The cooking demonstrations will be interactive and designed to provide individuals with prediabetes or who are at high risk of prediabetes, the skills they need to independently prepare healthy, balanced meals that support blood sugar management. The trained CHW and study team will be available to address participant questions or concerns during the 6-week cooking demonstration period. The study team will also conduct weekly check-ins with the participants during this period to collect surveys to measure satisfaction, nutritional knowledge, consumption of fruits and vegetables, and healthy eating habits. Dr. Castellon-Lopez and the study team will use standard surveys and open-ended questions to ensure that we capture the full range of perspectives from all the participants weekly and at the end of the 6-week intervention period, we will conduct audio-recorded interviews with the study participants. As this study does not involve randomization or comparison of different groups receiving different interventions, special methods for randomization are not required. Instead, the study will focus on qualitative and descriptive measures of feasibility and acceptability, such as participant feedback and engagement with nutritional intervention. The sample size was chosen based on the goal of gathering initial data on the intervention's feasibility rather than statistical comparisons or outcome changes. Data analysis will focus on understanding the intervention's feasibility within the existing DPP class structure and the acceptability of the intervention to the participants. As this is a feasibility study, our goal is to collect outcomes to plan for a future fully powered RCT and we do not anticipate having enough power to detect change in outcomes in the current study""}, 'conditionsModule': {'conditions': ['Prediabetic State', 'PreDiabetes', 'Health Knowledge, Attitudes, Practice', 'Nutrition, Healthy', 'Acceptability of Health Care', 'Obesity Prevention']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 20, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'DPP Clinic Participants', 'type': 'EXPERIMENTAL', 'description': ""A single arm approach with two groups of ten collected a two different time points in the year of the clinic's DPP. These will not be compared to each other they will be used to collect feasibility outcomes data to inform a future pilot randomized study"", 'interventionNames': ['Behavioral: One-arm feasibility pilot of a nutrition intervention to recruit, engage, and retain DPP participants in the safety-net setting in Los Angeles']}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'One-arm feasibility pilot of a nutrition intervention to recruit, engage, and retain DPP participants in the safety-net setting in Los Angeles', 'description': 'This clinical trial incorporates a behavioral intervention as the primary outcome of Aim 3 is to assess the feasibility and acceptability of adding an educational intervention using nutritional demonstrations aligned with the Diabetes Prevention Program (DPP) curriculum among patients who are at-risk for prediabetes. The purpose of this study is to assess if having a nutritional demonstration as part of the DPP would be accepted by clinic DPP patients and hear their perspectives about if this would help them in achieving DPP goals of achieving at least 5% weight loss and implementing sustainable lifestyle changes with healthy eating to reduce their risk of prediabetes. The intervention is designed to encourage healthier eating habits and encourage clinic DPP patients to incorporate this into their daily lives. This study will also determine if it is feasible to incorporate nutritional demonstrations to enhance the existing DPP curriculum', 'armGroupLabels': ['DPP Clinic Participants']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Retention', 'description': 'The primary outcome of this feasibility study will be retention in the DPP. Retention will be defined as participation in 9 of the 16 core DPP sessions during months 1 through 6 of the DPP. This measure will assess participant completion of the DPP. % retention will be measured at the end of the DPP.', 'timeFrame': 'Post-Intervention (12-months as DPP is a year-long program)'}], 'secondaryOutcomes': [{'measure': 'Recruitment Rate of Participants for Nutrition Intervention', 'description': 'Secondary outcomes of this feasibility study will be to assess the number of DPP patients recruited for this nutrition intervention study. This will be assessed initially at Baseline by total number enrolled and during the intervention (Weeks 1-6) by collecting participant attendance at each weekly nutrition intervention session to see if there is any change in attendance.', 'timeFrame': 'Baseline and During Intervention (Weeks 1-6)'}, {'measure': 'Change in Participant Acceptability of the Nutrition Intervention', 'description': ""Secondary outcomes of this feasibility study will be to assess participant acceptability of the nutrition intervention, as defined by satisfaction with the nutrition intervention's cooking demonstration activities. This will be measured via a weekly Likert scale, intervention satisfaction survey. At the end of the intervention (Week 6) participants will participate in a focus group to assess satisfaction and overall acceptability of the nutrition intervention"", 'timeFrame': 'During & Post Intervention (Weeks 1-6)'}], 'otherOutcomes': [{'measure': 'Healthy Food Environment Assessment', 'description': 'Using the 3-Item Healthy Food Environments Protocol, a self-reported food environment assessment, the study will measure the quality and availability of fresh fruit and vegetables and low-fat products in the local neighborhood. Higher mean scores indicate greater availability of healthy foods in the neighborhood (i.e., low-fat products, fruits, and vegetables).', 'timeFrame': 'Pre-Intervention at Baseline'}, {'measure': 'Change in Food Insecurity', 'description': 'Other outcomes of this feasibility study will collect data on participant experience with food insecurity. This will be evaluated using a 6-Item food Insecurity measure from U.S. Department of Agriculture Economic Research Service.', 'timeFrame': 'Pre- and Post-intervention (Baseline in Week 1, 12 months)'}, {'measure': 'Change in Self-Efficacy', 'description': 'Other outcomes of this feasibility study will collect a self-report measure of self-efficacy using the 10-item Generalized Self-Efficacy Scale (GSE)', 'timeFrame': 'Pre, During and Post-Intervention (Baseline in Week 1, Weekly during 6-wk intervention, Final session in 6th week)'}, {'measure': 'Change in Biometric Data', 'description': 'Other outcomes of this feasibility study will collect data on participant weight (this is already collected at DPP classes) HR, sleep hours. The purpose of collecting this data is to assess potential outcomes that should be collected in a future pragmatic and fully powered RCT comparing DPP + nutritional intervention and DPP alone.', 'timeFrame': 'Pre, During and Post-intervention (Baseline in Week 1, Weekly during 6-wk intervention, Final session in 6th week and at 12 months for DPP end)'}, {'measure': 'Change in Dietary Restraint w/ Eating', 'description': 'Using the 18-item, self-administered questionnaire with Likert-style questions, the study will measure participant dietary habits and restraint. This questionnaire measures cognitive restraint scale, uncontrolled eating scale and emotional eating scale and we will assess how this may influence participant dietary habits with eating', 'timeFrame': 'During Intervention (Weeks 1, 3 & 6) and 12mo'}, {'measure': 'Change in Dietary Habits', 'description': 'The Dietary Screener Questionnaire (DSQ) is a 30-item questionnaire from the National Health and Nutrition Examination Survey (NHANES) 2009-2010 series. The interview includes items about frequency of intake of various food items (per month, daily, etc.).', 'timeFrame': 'Pre-Intervention and Post-Intervention (Week 1 at Baseline and Week 6)'}, {'measure': 'Change in Quality of Life Indicators', 'description': ""Other outcomes of this feasibility study will collect a self-reported outcome measure assessing the impact of health on an individual's everyday life to assess quality of life through domains of 1) imitations in physical activities because of health problems 2) Limitations in social activities because of physical or emotional problems 3) Limitations in usual role activities because of physical health problems 4) Bodily pain 5) General mental health (psychological distress and well-being) 6) Limitations in usual role activities because of emotional problems 7) Vitality (energy and fatigue) 8)General health perceptions"", 'timeFrame': 'Pre, During and Post-Intervention (Baseline in Week 1, Weekly during 6-wk intervention, Final session in 6th week) and at 12mo'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* 18+ years old\n* BMI of 25 or higher (23 or higher if Asian)\n* Meet specific blood sugar test criteria indicating prediabetes, such as a fasting plasma glucose level between 110-125 mg/dL or an A1C level between 5.7-6.4%\n* Not be diagnosed with type 1 or type 2 diabetes\n* Moderate to high risk of having prediabetes or a known diagnosis of prediabetes by their medical provider in the last 12 months.\n* Eligible or enrolled in the Diabetes Prevention Program\n\nExclusion Criteria:\n\n* Younger than 18 years of age\n* BMI of less than 25 or higher (or under 23 if Asian)\n* Does not meet specific blood sugar test criteria indicating prediabetes, such as a fasting plasma glucose level between 110-125 mg/dL or an A1C level between 5.7-6.4%\n* Currently diagnosed with type 1 or type 2 diabetes\n* Has not been diagnosed as moderate to high risk of having prediabetes or having a known diagnosis of prediabetes by their medical provider in the last 12 months.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'maximumAge': '99 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Leslie Aguilar-Hernandez, BA', 'role': 'CONTACT', 'phone': '4243140443', 'email': 'leslie.aguilar-hernandez@cshs.org'}], 'overallOfficials': [{'name': 'Yelba Castellon-Lopez, MD', 'affiliation': 'Cedars-Sinai Medical Center', 'role': 'PRINCIPAL_INVESTIGATOR'}]}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D011236', 'term': 'Prediabetic State'}, {'id': 'D001519', 'term': 'Behavior'}, {'id': 'D010342', 'term': 'Patient Acceptance of Health Care'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D000074822', 'term': 'Treatment Adherence and Compliance'}, {'id': 'D015438', 'term': 'Health Behavior'}]}}",False,
"{'identificationModule': {'nctId': 'NCT07284979', 'orgStudyIdInfo': {'id': 'K9531-3107'}, 'secondaryIdInfos': [{'id': '2025-523511-11-00', 'type': 'CTIS'}], 'organization': {'fullName': 'Kailera', 'class': 'INDUSTRY'}, 'briefTitle': 'Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes', 'officialTitle': 'A Phase 3, Randomized, Active- and Placebo-Controlled, Partially-Blinded Study to Compare the Efficacy and Safety of KAI-9531 Administered Once Weekly Versus Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes'}, 'statusModule': {'statusVerifiedDate': '2025-12', 'overallStatus': 'NOT_YET_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-12', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2028-03-20', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2028-04-17', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2025-12-09', 'studyFirstSubmitQcDate': '2025-12-09', 'studyFirstPostDateStruct': {'date': '2025-12-16', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-17', 'lastUpdatePostDateStruct': {'date': '2025-12-18', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'Kailera', 'class': 'INDUSTRY'}}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.'}, 'conditionsModule': {'conditions': ['Obesity'], 'keywords': ['Obesity', 'KAI-9531', 'Glucagon-like peptide-1', 'GLP-1', 'Semaglutide', 'Glucose-dependent Insulinotropic Peptide', 'GIP']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'maskingDescription': 'The participant and investigator will be blinded for participants randomized to KAI-9531 or placebo until the study is complete. Semaglutide will be provided open-label.', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 1200, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'KAI-9531: Dose 1', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Dose 1 of KAI-9531 once weekly.', 'interventionNames': ['Drug: KAI-9531']}, {'label': 'KAI-9531: Dose 2', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Dose 2 of KAI-9531 once weekly.', 'interventionNames': ['Drug: KAI-9531']}, {'label': 'Semaglutide', 'type': 'ACTIVE_COMPARATOR', 'description': 'Participants will receive semaglutide once weekly.', 'interventionNames': ['Drug: Semaglutide']}, {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Participants will receive placebo matched to KAI-9531 once weekly.', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'type': 'DRUG', 'name': 'KAI-9531', 'description': 'SC Injection', 'armGroupLabels': ['KAI-9531: Dose 1', 'KAI-9531: Dose 2']}, {'type': 'DRUG', 'name': 'Semaglutide', 'description': 'SC Injection', 'armGroupLabels': ['Semaglutide'], 'otherNames': ['Wegovy']}, {'type': 'DRUG', 'name': 'Placebo', 'description': 'SC Injection', 'armGroupLabels': ['Placebo']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percent Change From Baseline in Body Weight at Week 76', 'timeFrame': 'Baseline, Week 76'}], 'secondaryOutcomes': [{'measure': 'Percentage of Participants with ≥10%, ≥15%, ≥20% and ≥25% Reduction in Body Weight', 'timeFrame': 'Baseline, Week 76'}, {'measure': 'Change From Baseline in Waist Circumference', 'timeFrame': 'Baseline, Week 76'}, {'measure': 'Change From Baseline in Absolute Body Weight', 'timeFrame': 'Baseline, Week 76'}, {'measure': 'Percentage of Participants with ≥5% Reduction in Body Weight', 'timeFrame': 'Baseline, Week 76'}, {'measure': 'Change From Baseline in Systolic Blood Pressure (SBP)', 'timeFrame': 'Baseline, Week 76'}, {'measure': 'Percent Change From Baseline in Fasting Triglycerides', 'timeFrame': 'Baseline, Week 76'}, {'measure': 'Percent Change From Baseline in Fasting High-density Lipoprotein (HDL)-cholesterol', 'timeFrame': 'Baseline, Week 76'}, {'measure': 'Percent Change From Baseline in Fasting Non-HDL-cholesterol', 'timeFrame': 'Baseline, Week 76'}, {'measure': 'Change From Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score', 'timeFrame': 'Baseline, Week 76'}, {'measure': 'Percentage of Participants with ≥30% Reduction in Body Weight', 'timeFrame': 'Baseline, Week 76'}, {'measure': 'Change From Baseline in Body Mass Index (BMI)', 'timeFrame': 'Baseline, Week 76'}, {'measure': 'Change From Baseline in Control of Eating Questionnaire (CoEQ) Craving Control Score', 'timeFrame': 'Baseline, Week 76'}, {'measure': 'Change From Baseline in CoEQ Positive Mood Score', 'timeFrame': 'Baseline, Week 76'}, {'measure': 'Change From Baseline in CoEQ Craving for Sweets Score', 'timeFrame': 'Baseline, Week 76'}, {'measure': 'Change From Baseline in CoEQ Craving for Savory Food Score', 'timeFrame': 'Baseline, Week 76'}, {'measure': 'Change From Baseline in CoEQ Hunger Score', 'timeFrame': 'Baseline, Week 76'}, {'measure': 'Change From Baseline in CoEQ Satiety Score', 'timeFrame': 'Baseline, Week 76'}, {'measure': 'Change From Baseline in CoEQ Combined Score', 'timeFrame': 'Baseline, Week 76'}, {'measure': 'Change From Baseline in Food Noise Questionnaire (FNQ) Score', 'timeFrame': 'Baseline, Week 76'}, {'measure': 'Number of Participants With Treatment-emergent Adverse Events (TEAEs)', 'timeFrame': 'Day 1 up to Week 80'}, {'measure': 'Number of Participants With Anti-drug Antibodies (ADAs)', 'timeFrame': 'Up to Week 80'}, {'measure': 'Number of Participants With Neutralizing Antibodies (Nabs)', 'timeFrame': 'Up to Week 80'}, {'measure': 'Plasma Concentrations of KAI-9531', 'timeFrame': 'Up to Week 76'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Key Inclusion Criteria:\n\n* BMI ≥35 kilograms per square meter (kg/m\\^2).\n* History of at least 1 self-reported unsuccessful effort to lose weight with diet and exercise within the prior 6 months.\n\nKey Exclusion Criteria:\n\n* Current diagnosis or history of diabetes mellitus.\n* Started medications within 3 months prior to Screening that may cause significant weight gain, including, but not limited to, tricyclic antidepressants, atypical antipsychotics, and mood stabilizers.\n* Unstable weight defined as self-reported change in body weight exceeding 5% within the 3 months prior to Screening.\n* Family or personal history of multiple endocrine neoplasia Type 2 or medullary thyroid cancer.\n* Uncontrolled hypertension or unstable cardiovascular disease.\n* History of chronic or acute pancreatitis.\n* Known clinically significant gastric-emptying abnormality or chronic treatment with medications that directly affect gastrointestinal motility.\n* History of suicide attempt.\n* History of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder.\n* Received treatment with semaglutide, tirzepatide, glucagon-like peptide-1 receptor (GLP-1R) agonist, GLP-1/glucose-dependent insulinotropic polypeptide (GIP), or glucagon receptor agonist within 3 months prior to Screening.\n\nNote: Additional inclusion/exclusion criteria may apply, per protocol.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Kailera Therapeutics, Inc.', 'role': 'CONTACT', 'phone': '781-317-0291', 'email': 'info-clinicalstudies@kailera.com'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009765', 'term': 'Obesity'}], 'ancestors': [{'id': 'D050177', 'term': 'Overweight'}, {'id': 'D044343', 'term': 'Overnutrition'}, {'id': 'D009748', 'term': 'Nutrition Disorders'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D001835', 'term': 'Body Weight'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000591245', 'term': 'semaglutide'}]}}",False,
"{'identificationModule': {'nctId': 'NCT06445946', 'orgStudyIdInfo': {'id': '2024H0193'}, 'organization': {'fullName': 'Ohio State University', 'class': 'OTHER'}, 'briefTitle': 'DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes', 'officialTitle': 'DECIDE: A Comparative Effectiveness Trial of Oral Metformin Versus Injectable Insulin for the Treatment of Gestational Diabetes', 'acronym': 'DECIDE'}, 'statusModule': {'statusVerifiedDate': '2025-10', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-08-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2029-12', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2030-12', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-05-21', 'studyFirstSubmitQcDate': '2024-06-04', 'studyFirstPostDateStruct': {'date': '2024-06-06', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-10-03', 'lastUpdatePostDateStruct': {'date': '2025-10-06', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Kartik K Venkatesh', 'investigatorTitle': 'Assistant Professor', 'investigatorAffiliation': 'Ohio State University'}, 'leadSponsor': {'name': 'Ohio State University', 'class': 'OTHER'}, 'collaborators': [{'name': 'Patient-Centered Outcomes Research Institute', 'class': 'OTHER'}, {'name': 'The George Washington University Biostatistics Center', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'This is a non-inferiority patient-centered and pragmatic comparative-effectiveness pregnancy randomized controlled trial (RCT) with postpartum maternal and child follow-up through 2 years of 1,572 individuals with gestational diabetes mellitus (GDM) randomized to oral metformin versus injectable insulin.\n\nThis study will determine if metformin is not inferior to insulin in reducing adverse pregnancy outcomes, is comparably safe for exposed individuals and children, and if patient-reported factors, including facilitators of and barriers to use, differ between metformin and insulin. A total of 1,572 pregnant individuals with GDM who need pharmacotherapy will be recruited at 20 U.S. sites using consistent treatment criteria to metformin versus insulin. Participants and their children will be followed through delivery to two years postpartum.', 'detailedDescription': 'Gestational diabetes mellitus (GDM) is one of the most common medical complications of pregnancy. Glycemic control decreases the risk of adverse pregnancy outcomes for the pregnant individual with GDM and the infant exposed in utero (1). One in four individuals with GDM will require pharmacotherapy to achieve glycemic control. Insulin has been the mainstay of pharmacotherapy. Metformin is an alternative option increasingly used in clinical practice (2). Both insulin and metformin reduce the risk of adverse pregnancy outcomes, but comparative effectiveness data from a well-characterized, adequately powered, and diverse U.S. population remain lacking (3). Because metformin crosses the placenta, long-term safety data, in particular the risk of childhood obesity, from exposed children are also needed. In addition, the patient-reported experiences of individuals with GDM requiring pharmacotherapy remains to be characterized, including barriers for and facilitators of metformin versus insulin use.\n\nIn a two-arm open-label, pragmatic comparative effectiveness randomized controlled trial (RCT), the DECIDE Study will examine whether metformin is not inferior to insulin in reducing adverse pregnancy outcomes and is comparably safe for exposed mothers and children, and whether patient-reported factors, including facilitators of and barriers to use, differ between metformin versus insulin use. The DECIDE Study Consortium will recruit and retain 1,572 pregnant individuals with GDM who need pharmacotherapy at 20 U.S. sites to metformin versus insulin and follow them and their children through delivery and then to 2-years\n\nPrimary aim:\n\nTo evaluate whether outcomes in pregnant individuals randomized to metformin are not inferior to those in pregnant individuals randomized to insulin for the composite adverse neonatal outcome defined as large-for-gestational-age birthweight (LGA), hypoglycemia, hyperbilirubinemia, or death.\n\nSecondary aims:\n\n1. To evaluate whether mean child body mass index (BMI) at 2 years of age is higher in the offspring of pregnant individuals randomized to metformin.\n2. To conduct a qualitative or mixed-methods analyses on a subgroup of participants to understand facilitators and barriers associated with metformin versus insulin use and heterogeneity of treatment effects (HTE) to facilitate evidence-based pharmacotherapy.\n3. To evaluate whether pregnant individuals randomized to metformin have equivalent maternal (hypertensive disorder of pregnancy, gestational weight gain, mode of delivery, and obstetric anal sphincter injuries) and neonatal (preterm birth, mechanical ventilation, NICU admission, oxygen support, and respiratory distress syndrome) outcomes.\n4. To evaluate whether pregnant individuals randomized to metformin have equivalent maternal (obesity, anthropometry, adiposity, diabetes, hypertension, cholesterol, and metabolic profile) and child (obesity, anthropometry, and adiposity) outcomes at 2-years postpartum.\n5. To evaluate whether pregnant individuals randomized to metformin have equivalent patient-reported outcomes (PROs), as measured at 6 weeks postpartum and at 2 years postpartum.'}, 'conditionsModule': {'conditions': ['Gestational Diabetes Mellitus', 'Pregnancy, High Risk'], 'keywords': ['Insulin', 'Pregnancy', 'Glycemic control', 'Metformin', 'Gestational diabetes', 'Diabetes', 'Adverse pregnancy outcomes']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 1572, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Metformin', 'type': 'EXPERIMENTAL', 'description': 'Metformin as either immediate- or extended-release formulations can be utilized, and titrated to a maximum daily dose of 2,500 mg. Participants receiving metformin will have insulin added only if they have not achieved euglycemia for at least 30% of glucose values after generally receiving the maximum daily dose of metformin of 2,500 mg, or in select situations in the setting of participant intolerance due to mild gastrointestinal symptoms. Participants will be asked to continue taking metformin after treatment supplementation with insulin.', 'interventionNames': ['Drug: Metformin']}, {'label': 'Insulin', 'type': 'EXPERIMENTAL', 'description': ""Insulin will be initiated utilizing clinical standards using trimester-specific weight-based dosing criteria, including both basal and prandial insulins for up to a total of 4 daily injections. Consistent with clinical practice, some people may be managed with a single dose of intermediate- or long-acting insulin at night to treat isolated fasting hyperglycemia, while others may require additional treatment of postprandial hyperglycemia with shorter-acting insulin. The sites' insulin formularies include rapid- (Novolog and Humalog), intermediate- (Humulin N, Novolin N, and NPH), and long-acting insulins (Detemir and Lantus)."", 'interventionNames': ['Drug: Insulin']}], 'interventions': [{'type': 'DRUG', 'name': 'Metformin', 'description': 'Individuals randomized to this arm will receive oral metformin tablets for their Gestational diabetes mellitus treatment.', 'armGroupLabels': ['Metformin']}, {'type': 'DRUG', 'name': 'Insulin', 'description': 'Individuals randomized to this arm will receive injectable insulin for their Gestational diabetes mellitus treatment.', 'armGroupLabels': ['Insulin']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'A neonatal composite adverse outcome of large-for-gestational-age (LGA) birthweight, hypoglycemia, hyperbilirubinemia, and/or death.', 'description': 'LGA will be defined as a birthweight ≥90th%tile for gestational age based on a US birth certificate reference adjusted for parity and/or fetal sex. Neonatal hypoglycemia will be defined as a blood glucose \\<35 mg/dL or treatment \\<24 hours after birth with either IV, PO, or gel glucose therapy. Neonatal hyperbilirubinemia will be defined as treated with phototherapy or exchange transfusion in the first postnatal week and either treatment in the first postnatal week or kernicterus. Fetal or neonatal death can be due to any indication between randomization to hospital discharge or 30 days postnatal if still hospitalized (excluding voluntary pregnancy termination).', 'timeFrame': 'LGA at birth. Hypoglycemia <24 hours after birth. Hyperbilirubinemia within the first week after birth. Death between randomization to hospital discharge or 30 days postnatal.'}, {'measure': 'Child body mass index (BMI) at 2 years of age', 'description': 'Child BMI measured in kg/m2 as a continuous measure standardized using U.S. CDC reference adjusted for child sex', 'timeFrame': '2 years of age.'}], 'secondaryOutcomes': [{'measure': 'Hypertensive disorder of pregnancy, HDP (maternal)', 'description': 'HDP will include either gestational hypertension or preeclampsia. Gestational hypertension will be defined as: systolic blood pressure of 140 mm Hg or more or diastolic blood pressure of 90 mm Hg or more on two occasions at least 4 hours apart after 20 weeks of gestation in a woman with a previously normal blood pressure. Preeclampsia will be defined as: above blood pressure criteria AND proteinuria (300 mg or more per 24 hour urine collection, protein/creatinine ratio of 0.3 mg/dL or more, or dipstick reading of 2+) OR thrombocytopenia (platelet count less than 100 109/L), renal insufficiency (serum creatinine greater than 1.1 mg/dL or a doubling of the serum creatinine concentration in the absence of other renal disease), impaired liver function (elevated blood concentrations of liver transaminases to twice normal concentration), pulmonary edema, new-onset headache or visual symptoms not attributed to other diagnoses.', 'timeFrame': 'Randomization to delivery'}, {'measure': 'Gestational weight gain (maternal)', 'description': 'Gestational weight gain between weight at first prenatal visit and weight at delivery based on z-score and defined as excess versus within Institute of Medicine (IOM) recommendations based on first pregnancy BMI.', 'timeFrame': 'Initiation of prenatal care to delivery'}, {'measure': 'Mode of delivery (maternal)', 'description': 'Cesarean delivery or vaginal delivery', 'timeFrame': 'At birth'}, {'measure': 'Obstetric perineal/anal sphincter injuries (maternal)', 'description': 'First degree: Injury to perineal skin only; Second degree: Injury to perineum involving perineal muscles but not involving anal sphincter; Third degree: Injury to perineum involving anal sphincter complex, including 3a: Less than 50% of external anal sphincter thickness torn; 3b: More than 50% external anal sphincter thickness torn; and 3c: Both external anal sphincter and internal anal sphincter torn; and Fourth degree: Injury to perineum involving anal sphincter complex (external anal sphincter and internal anal sphincter) and anal epithelium.', 'timeFrame': 'At birth'}, {'measure': 'Preterm birth (child)', 'description': 'Preterm birth \\<37 weeks and \\<34 weeks based on project gestational age', 'timeFrame': 'At birth'}, {'measure': 'Requiring mechanical ventilation (child)', 'description': 'Intubation, continuous positive airway pressure (CPAP) or high-flow nasal cannula (HFNC) for ventilation or cardiopulmonary resuscitation within first 72 hours of birth', 'timeFrame': '<72 hours after birth'}, {'measure': 'NICU admission (child)', 'description': 'Admitted to NICU or intermediate nursery ≥72 hours, any indication', 'timeFrame': 'Birth to delivery discharge.'}, {'measure': 'Oxygen support (child)', 'description': 'Requiring oxygen support', 'timeFrame': '<72 hours after birth'}, {'measure': 'Respiratory distress syndrome (child)', 'description': 'Signs of respiratory distress with oxygen requirement and confirmed by chest x-ray.', 'timeFrame': 'Anytime during the first 72 hours after birth'}, {'measure': 'Body mass index (BMI) (maternal)', 'description': 'Continuous measure, using standardized protocol as kg/m2.', 'timeFrame': '2-year follow-up'}, {'measure': 'Obesity overall and by class (maternal)', 'description': 'BMI per the following classifications: Normal or underweight: \\< 25 kg/m2; Overweight: 25 to \\< 30 kg/m2; Class 1: 30 to \\< 35 kg/m2; Class 2: 35 to \\< 40 kg/m2; and Class 3: 40 kg/m2 or greater.', 'timeFrame': '2-year follow-up'}, {'measure': 'Anthropometry (maternal)', 'description': 'Waist circumference, continuous measures in cm', 'timeFrame': '2-year follow-up'}, {'measure': 'Anthropometry (maternal)', 'description': 'Hip circumference, continuous measures in cm', 'timeFrame': '2-year follow-up'}, {'measure': 'Anthropometry (maternal)', 'description': 'Waist - to - hip ratio, continuous measure', 'timeFrame': '2-year follow-up'}, {'measure': 'Adiposity (maternal)', 'description': 'Triceps, subscapular, suprailiac skinfolds, continuous measures in cm', 'timeFrame': '2 year follow-up'}, {'measure': 'Type 2 diabetes (maternal)', 'description': 'A1c \\> 6.5% OR fasting plasma glucose \\> 126 mg/dL OR OGTT \\> 200 mg/dL OR prior diagnosis per patient report', 'timeFrame': '2-year follow-up.'}, {'measure': 'Prediabetes (maternal)', 'description': 'A1c 5.7% to 6.4% OR fasting plasma glucose 100 mg/dl to 125 mg/dL OR OGTT 140 to 199 mg/dL', 'timeFrame': '2-year follow-up.'}, {'measure': 'Hypertension (maternal)', 'description': 'Per American Heart Association criteria as below and/or antihypertensive medication or prior diagnosis per patient report, and defined as: Elevated: Systolic between 120-129 and diastolic less than 80 mm Hg; Stage 1: Systolic between 130-139 or diastolic between 80-89 mm Hg; and Stage 2: Systolic at least 140 or diastolic at least 90 mm Hg.', 'timeFrame': '2-year follow-up.'}, {'measure': 'Cholesterol (maternal)', 'description': 'Fasting state, defined as a continuous measure and dichotomous at the following thresholds for each component: Total cholesterol: \\> 200 mg/dL; LDL cholesterol: \\> mg/dL; HDL cholesterol: \\< 40 mg/dL; Triglycerides: \\> 200 mg/dL.', 'timeFrame': '2-year follow-up.'}, {'measure': 'Hemoglobin A1c (maternal)', 'description': 'Continuous measure, percentage.', 'timeFrame': '2-year follow-up.'}, {'measure': 'Overweight (child)', 'description': 'BMI ≥85th%tile for age and sex.', 'timeFrame': '2-year follow-up.'}, {'measure': 'Obesity (child)', 'description': 'BMI ≥95th%tile for age and sex.', 'timeFrame': '2-year follow-up.'}, {'measure': 'Anthropometry (child)', 'description': 'Abdominal circumference; age- and sex-adjusted per WHO z-scores for arm circumference.', 'timeFrame': '2-year follow-up.'}, {'measure': 'Adiposity (child)', 'description': 'Triceps/subscapular skinfold thickness \\> 90th%tile for age and sex; individual and sum of measures.', 'timeFrame': '2-year follow-up.'}, {'measure': 'Treatment Satisfaction Questionnaire for Medication (TSQM)', 'description': 'The TSQM (version 1.4) comprises 14 items across four domains focusing on effectiveness (three items), side effects (five items), convenience (three items), and global satisfaction (three items) of the medication over the previous 2-3 weeks. With the exception of item 4 (presence of side effects; yes or no), all items have five or seven responses, scored from one (least satisfied) to five or seven (most satisfied). Item scores are summed to give four domain scores, which are in turn transformed to a scale of 0-100. Item 4 was not included for scoring.', 'timeFrame': '6-weeks postpartum.'}, {'measure': 'Questionnaire on Acceptability of Treatment', 'description': 'A set of 5 questions developed in the Rowan et al. RCT assessing patient adherence, preferences, and experiences with metformin versus insulin for GDM (Rowan et al., NEJM, 2008).', 'timeFrame': '6-weeks postpartum.'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* Singleton gestation. Twin reduction to singleton, either spontaneously or therapeutically, is eligible if it occurred before 14 weeks gestational age.\n* Age 18 years or older\n* Gestational age at randomization between 20 0/7 - 33 6/7 weeks based on project gestational age.\n* GDM diagnosis less than or equal to 33 6/7 weeks based on project gestational age.\n* Requires medication for glucose control defined as ≥ 30% elevated glucose values (either fasting or postprandial or both) prior to randomization per determination of the provider or documented in the medical record.\n* Patient willingness and ability to attend 2-year follow-up visit.\n\nExclusion criteria:\n\n* Renal disease (serum creatinine \\>1.3 mg/dL) due to the potential impact of metformin on renal function.\n* Major structural malformation of the fetus.\n* Known fetal aneuploidy based on invasive testing or positive for aneuploidy on cell-free fetal DNA screening.\n* Contraindication to metformin or insulin, including: history of lactic acidosis, intractable nausea and vomiting, prior documented allergy and/or anaphylaxis.\n* For individuals with GDM diagnosed \\<20 0/7 weeks, documented A1c ≥\\>6.5% within prior 6 months.\n* Pregestational diabetes documented in the medical record or prior A1c\\>= 6.5%\n* Fasting hyperglycemia \\>115 mg/dl for ≥ 50% of fasting glucose values in the past week (due to the high risk of metformin failure with fasting hyperglycemia).\n* Enrolled in a trial that influences primary study outcomes (composite neonatal outcome at delivery or childhood body mass index at 2 years).\n* Prenatal care or delivery planned at a location where access to the complete electronic medical record will not be available to research staff.\n* Language barrier (appropriate translation resources unavailable at the site)\n* Participation in this trial in a previous pregnancy. Patients who were screened in a previous pregnancy, but not randomized, may be included.', 'healthyVolunteers': False, 'sex': 'FEMALE', 'genderBased': True, 'genderDescription': 'This study is restricted to pregnant individuals.', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Kartik Venkatesh, MD, PhD', 'role': 'CONTACT', 'phone': '614-293-2222', 'email': 'kartik.venkatesh@osumc.edu'}, {'name': 'Anna Bartholomew, MPH, BS, RN', 'role': 'CONTACT', 'phone': '614-685-3229', 'email': 'Anna.Bartholomew@osumc.edu'}], 'overallOfficials': [{'name': 'Kartik Venkatesh, MD, PhD', 'affiliation': 'Ohio State University', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'University of Alabama', 'status': 'RECRUITING', 'city': 'Tuscaloosa', 'state': 'Alabama', 'zip': '35487', 'country': 'United States', 'contacts': [{'name': 'Ashley Battarbee, MD', 'role': 'CONTACT', 'email': 'anbattarbee@uabmc.edu'}, {'name': 'Michael Jordan', 'role': 'CONTACT', 'email': 'mejordan@uabmc.edu'}, {'name': 'Ashley Battarbee, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 33.20984, 'lon': -87.56917}}, {'facility': 'Cedars Sinai Medical Center', 'status': 'RECRUITING', 'city': 'Los Angeles', 'state': 'California', 'zip': '90048', 'country': 'United States', 'contacts': [{'name': 'Tania Esakoff, MD', 'role': 'CONTACT', 'email': 'Tania.esakoff@cshs.org'}, {'name': 'Marla Sharp', 'role': 'CONTACT', 'email': 'Marla.Sharp@cshs.org'}, {'name': 'Tania Esakoff, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'facility': 'University of California San Francisco', 'status': 'RECRUITING', 'city': 'San Francisco', 'state': 'California', 'zip': '94143', 'country': 'United States', 'contacts': [{'name': 'Nasim Sobhani, MD', 'role': 'CONTACT', 'email': 'Nasim.sobhani@ucsf.edu'}, {'name': 'Magie Fong', 'role': 'CONTACT', 'email': 'magie.fong@ucsf.edu'}, {'name': 'Nasim Sobhani, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'facility': 'Christiana Care', 'status': 'RECRUITING', 'city': 'Newark', 'state': 'Delaware', 'zip': '19718', 'country': 'United States', 'contacts': [{'name': 'Anthony Sciscione, MD', 'role': 'CONTACT', 'email': 'asciscione@christianacare.org'}, {'name': 'Carrie Kitto', 'role': 'CONTACT', 'email': 'CKitto@christianacare.org'}, {'name': 'Anthony Sciscione, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Matthew Hoffman, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 39.68372, 'lon': -75.74966}}, {'facility': 'University of South Florida', 'status': 'RECRUITING', 'city': 'Tampa', 'state': 'Florida', 'zip': '33620', 'country': 'United States', 'contacts': [{'name': 'Anjali Kaimal Kaimal, MD', 'role': 'CONTACT', 'email': 'akaimal@usf.edu'}, {'name': 'Maha Jumaily', 'role': 'CONTACT', 'email': 'mahaaljumaily@usf.edu'}, {'name': 'Anjali Kaimal, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'facility': 'Tufts University', 'status': 'RECRUITING', 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02111', 'country': 'United States', 'contacts': [{'name': 'Erika Werner, MD', 'role': 'CONTACT', 'email': 'erika.werner@tuftsmedicine.org'}, {'name': 'Beth Marsh', 'role': 'CONTACT', 'email': 'Beth.Marsh@tuftsmedicine.org'}, {'name': 'Erika Werner, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Patrick Catalano, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'facility': 'Massachusetts General Hospital', 'status': 'RECRUITING', 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02114', 'country': 'United States', 'contacts': [{'name': 'Lydia Shook, MD', 'role': 'CONTACT', 'email': 'lshook@mgh.harvard.edu'}, {'name': 'Nancy Kingori', 'role': 'CONTACT', 'email': 'nkingori@mgb.org'}, {'name': 'Lydia Shook, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Camille Powe, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Lauren Fiechtner, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'facility': 'Beth Israel Deaconess Medical Center', 'status': 'RECRUITING', 'city': 'Boston', 'state': 'Massachusetts', 'zip': '02215', 'country': 'United States', 'contacts': [{'name': 'Chloe Zera, MD', 'role': 'CONTACT', 'email': 'czera@bidmc.harvard.edu'}, {'name': 'Andy Ngyuen', 'role': 'CONTACT', 'email': 'anguye13@bidmc.harvard.edu'}, {'name': 'Chloe Zera, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'facility': 'University of New Mexico', 'status': 'RECRUITING', 'city': 'Albuquerque', 'state': 'New Mexico', 'zip': '87131', 'country': 'United States', 'contacts': [{'name': 'Vivek Katukuri, MD', 'role': 'CONTACT', 'email': 'vkatukuri@salud.unm.edu'}, {'name': 'Karen Taylor', 'role': 'CONTACT', 'email': 'kataylor@salud.unm.edu'}, {'name': 'Vivek Katukuri, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 35.08449, 'lon': -106.65114}}, {'facility': 'Columbia University Irving Medical Center', 'status': 'RECRUITING', 'city': 'New York', 'state': 'New York', 'zip': '10032', 'country': 'United States', 'contacts': [{'name': 'Noelia Zork, MD', 'role': 'CONTACT', 'email': 'nmz2110@cumc.columbia.edu'}, {'name': 'Joseph Celentano', 'role': 'CONTACT', 'email': 'jmc2476@cumc.columbia.edu'}, {'name': 'Noelia Zork, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'facility': 'Wake Forest University', 'status': 'RECRUITING', 'city': 'Winston-Salem', 'state': 'North Carolina', 'zip': '27106', 'country': 'United States', 'contacts': [{'name': 'David Stamilio, MD', 'role': 'CONTACT', 'email': 'dstamili@wakehealth.edu'}, {'name': 'Christina Tulbert', 'role': 'CONTACT', 'email': 'ctulbert@wakehealth.edu'}, {'name': 'David Stamilio, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 36.09986, 'lon': -80.24422}}, {'facility': 'The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine', 'status': 'RECRUITING', 'city': 'Columbus', 'state': 'Ohio', 'zip': '43210', 'country': 'United States', 'contacts': [{'name': 'Kartik Venkatesh, MD, PhD', 'role': 'CONTACT', 'phone': '614-293-2222', 'email': 'Kartik.Venkatesh@osumc.edu'}, {'name': 'Kartik Venkatesh, MD, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Mark Landon, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Maged Costantine, MD, MBA', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Ann S McAlearney, ScD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Anne Trinh, MPH', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Steven Gabbe, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Christine Field, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'facility': 'Premier Health - Miami Valley Hospital', 'status': 'RECRUITING', 'city': 'Dayton', 'state': 'Ohio', 'zip': '45409', 'country': 'United States', 'contacts': [{'name': 'Samantha Wiegand, MD', 'role': 'CONTACT', 'email': 'slwiegand@premierhealth.com'}, {'name': 'Emily Reynolds', 'role': 'CONTACT', 'email': 'ESReynolds@premierhealth.com'}, {'name': 'Samantha Wiegand, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 39.75895, 'lon': -84.19161}}, {'facility': 'University of Pittsburgh', 'status': 'RECRUITING', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'zip': '15213', 'country': 'United States', 'contacts': [{'name': 'Maisa Feghali, MD', 'role': 'CONTACT', 'email': 'feghalim@mwri.magee.edu'}, {'name': 'John Collins', 'role': 'CONTACT', 'email': 'collinsjn@mwri.magee.edu'}, {'name': 'Maisa Feghali, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'facility': 'Brown University', 'status': 'RECRUITING', 'city': 'Providence', 'state': 'Rhode Island', 'zip': '02912', 'country': 'United States', 'contacts': [{'name': 'Martha Kole-White, MD', 'role': 'CONTACT', 'email': 'mkolewhite@kentri.org'}, {'name': 'Kelsey Inglesby', 'role': 'CONTACT', 'email': 'KInglesby@Wihri.org'}, {'name': 'Martha Kole-White, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 41.82399, 'lon': -71.41283}}, {'facility': 'University of South Carolina Greenville', 'status': 'RECRUITING', 'city': 'Greenville', 'state': 'South Carolina', 'zip': '29605', 'country': 'United States', 'contacts': [{'name': 'Kacey Eichelberger, MD', 'role': 'CONTACT', 'email': 'kacey.eichelberger@prismahealth.org'}, {'name': 'Patti Parker', 'role': 'CONTACT', 'email': 'patti.parker@prismahealth.org'}, {'name': 'Kacey Eichelberger, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 34.85262, 'lon': -82.39401}}, {'facility': 'University of Texas Austin', 'status': 'RECRUITING', 'city': 'Austin', 'state': 'Texas', 'zip': '78705', 'country': 'United States', 'contacts': [{'name': 'Lorie Harper, MD', 'role': 'CONTACT', 'email': 'lorie.harper@austin.utexas.edu'}, {'name': 'Mickey Roberts', 'role': 'CONTACT', 'email': 'Mickey.roberts@austin.utexas.edu'}, {'name': 'Lorie Harper, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 30.26715, 'lon': -97.74306}}, {'facility': 'University of Texas Health Science Center', 'status': 'RECRUITING', 'city': 'Houston', 'state': 'Texas', 'zip': '77030', 'country': 'United States', 'contacts': [{'name': 'Hector Mendez-Figueroa, MD', 'role': 'CONTACT', 'email': 'hector.mendezfigueroa@uth.tmc.edu'}, {'name': 'Laura Nixon', 'role': 'CONTACT', 'email': 'Laura.Nixon@uth.tmc.edu'}, {'name': 'Hector Mendez-Figueroa, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'facility': 'Eastern Virginia Medical School - Old Dominion University', 'status': 'RECRUITING', 'city': 'Norfolk', 'state': 'Virginia', 'zip': '23501', 'country': 'United States', 'contacts': [{'name': 'Malgorzata Mlynarczyk, MD', 'role': 'CONTACT', 'email': 'mlynarm@evms.edu'}, {'name': 'Cheryl Sparrer', 'role': 'CONTACT', 'email': 'SparreCD@evms.edu'}, {'name': 'Malgorzata Mlynarczyk, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'George Saade, MD', 'role': 'SUB_INVESTIGATOR'}], 'geoPoint': {'lat': 36.84681, 'lon': -76.28522}}]}, 'referencesModule': {'references': [{'pmid': '34605130', 'type': 'BACKGROUND', 'citation': 'Venkatesh KK, Chiang CW, Castillo WC, Battarbee AN, Donneyong M, Harper LM, Costantine M, Saade G, Werner EF, Boggess KA, Landon MB. Changing patterns in medication prescription for gestational diabetes during a time of guideline change in the USA: a cross-sectional study. BJOG. 2022 Feb;129(3):473-483. doi: 10.1111/1471-0528.16960. Epub 2021 Nov 8.'}, {'pmid': '38049101', 'type': 'BACKGROUND', 'citation': 'Venkatesh KK, Wu J, Trinh A, Cross S, Rice D, Powe CE, Brindle S, Andreatta S, Bartholomew A, MacPherson C, Costantine MM, Saade G, McAlearney AS, Grobman WA, Landon MB. Patient Priorities, Decisional Comfort, and Satisfaction with Metformin versus Insulin for the Treatment of Gestational Diabetes Mellitus. Am J Perinatol. 2024 May;41(S 01):e3170-e3182. doi: 10.1055/s-0043-1777334. Epub 2023 Dec 4.'}, {'pmid': '35412565', 'type': 'BACKGROUND', 'citation': 'Venkatesh KK, Lynch CD, Powe CE, Costantine MM, Thung SF, Gabbe SG, Grobman WA, Landon MB. Risk of Adverse Pregnancy Outcomes Among Pregnant Individuals With Gestational Diabetes by Race and Ethnicity in the United States, 2014-2020. JAMA. 2022 Apr 12;327(14):1356-1367. doi: 10.1001/jama.2022.3189.'}, {'pmid': '39317491', 'type': 'DERIVED', 'citation': 'Venkatesh KK, MacPherson C, Clifton RG, Powe CE, Bartholomew A, Gregory D, Trinh A, McAlearney AS, Fiechtner LG, Catalano P, Rice D, Cross S, Kutay H, Gabbe S, Grobman WA, Costantine MM, Battarbee AN, Boggess K, Katukuri V, Eichelberger K, Esakoff T, Feghali MN, Harper L, Kaimal A, Kole-White M, Mendez-Figueroa H, Mlynarczyk M, Sciscione A, Shook L, Sobhani NC, Stamilio DM, Werner E, Wiegand S, Zera CA, Zork NM, Saade G, Landon MB. Comparative effectiveness trial of metformin versus insulin for the treatment of gestational diabetes in the USA: clinical trial protocol for the multicentre DECIDE study. BMJ Open. 2024 Sep 24;14(9):e091176. doi: 10.1136/bmjopen-2024-091176.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'PCORI guidelines for data sharing will be followed, including the release of the Analyzable Data Set. This is the final cleaned and locked data set that contains all the data used in conducting the analyses reported in the PCORI Final Research Report and is de-identified in accordance with the HIPAA Privacy Rule.', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF', 'CSR', 'ANALYTIC_CODE'], 'timeFrame': 'Data will be available on website in March 2030.', 'accessCriteria': 'Users interested in obtaining these data must complete a Restricted Data Use Agreement, specify the reason for the request, and obtain IRB approval or notice of exemption for their research.', 'url': 'https://www.icpsr.umich.edu/web/pages/pcodr/'}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D016640', 'term': 'Diabetes, Gestational'}, {'id': 'D007333', 'term': 'Insulin Resistance'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}], 'ancestors': [{'id': 'D011248', 'term': 'Pregnancy Complications'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D006946', 'term': 'Hyperinsulinism'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D008687', 'term': 'Metformin'}, {'id': 'D007328', 'term': 'Insulin'}], 'ancestors': [{'id': 'D001645', 'term': 'Biguanides'}, {'id': 'D006146', 'term': 'Guanidines'}, {'id': 'D000578', 'term': 'Amidines'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D011384', 'term': 'Proinsulin'}, {'id': 'D061385', 'term': 'Insulins'}, {'id': 'D010187', 'term': 'Pancreatic Hormones'}, {'id': 'D036361', 'term': 'Peptide Hormones'}, {'id': 'D006728', 'term': 'Hormones'}, {'id': 'D006730', 'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'}, {'id': 'D010455', 'term': 'Peptides'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}]}}",False,
"{'identificationModule': {'nctId': 'NCT06896799', 'orgStudyIdInfo': {'id': '25/NI/0004'}, 'organization': {'fullName': ""Queen's University, Belfast"", 'class': 'OTHER'}, 'briefTitle': 'Determining the Effect of Food Ordering on Blood Glucose In Gestational Diabetes Mellitus (DEFI-GDM)', 'officialTitle': 'Determining the Effect of Food Ordering on Blood Glucose In Gestational Diabetes Mellitus (DEFI-GDM) - a Randomised Crossover Study', 'acronym': 'DEFI-GDM'}, 'statusModule': {'statusVerifiedDate': '2025-12', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2025-12-11', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-09-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2027-02-01', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2025-03-04', 'studyFirstSubmitQcDate': '2025-03-24', 'studyFirstPostDateStruct': {'date': '2025-03-26', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-12-12', 'lastUpdatePostDateStruct': {'date': '2025-12-15', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Jayne Woodside, PhD', 'investigatorTitle': 'Professor', 'investigatorAffiliation': ""Queen's University, Belfast""}, 'leadSponsor': {'name': ""Queen's University, Belfast"", 'class': 'OTHER'}, 'collaborators': [{'name': 'Imperial College London', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'The goal of this clinical trial is to determine whether the sequence of macronutrient consumption affects post-prandial glycaemia in women with gestational diabetes mellitus.\n\nThe main questions it aims to answer are:\n\n* The difference in the magnitude of postprandial rise in blood glucose between the two test meals.\n* The difference in the magnitude of postprandial change in serum levels of gut hormones between the two test meals.\n* The difference in mean change in pre-post ingestion satiety scores between the two test meals.\n* The difference in 24 hour energy and macronutrient intake following the two test meals.\n\nParticipants will attend two study visits at the Centre for Public Health, with an interval of at least two days between the visits and complete the following, anthropometric measurements, demographic and appetite questionnaires, glucose measurements, two food diaries and fasting blood samples and the consumption of the study breakfast. Participants will be asked to eat either the protein/fat-based component of the meal (scrambled egg) before or after the carbohydrate-based component (wholemeal toast) on their first visit and on the other visit they will be asked to eat the meal in the reverse order. The order in which this occurs will be randomised and each participant will act as their own control. Researchers will compare the results from participants between the two test meals to see if the order of macronutrient consumption has any effect on post-prandial glycaemia, gut hormones, satiety scores and energy and macronutrient intake.', 'detailedDescription': ""Gestational diabetes mellitus (GDM) is glucose intolerance with onset or first diagnosis during pregnancy, affecting around 1 in 10 pregnancies in the United Kingdom (UK). Women with GDM are 10 times more likely to develop type 2 DM and twice as likely to develop cardiovascular disease in later life than women without GDM. Dietary modification is recommended as first line management to optimise blood glucose control. However, this often fails, necessitating the use of medication such as metformin and insulin. There is a pressing need to find safe and effective dietary approaches to optimise glycaemic control in GDM which can be easily adhered to in order to improve longer-term outcomes. The impact of the sequence of macronutrients on glycaemic control is an emerging area of interest. Recent evidence suggests that the consumption of the fat/protein components of a meal prior to the carbohydrate components, reduces the peak by around 40% after food. This study aims to determine whether the order that macronutrients (i.e. protein, fat, carbohydrate) are eaten affects; blood sugar glucose levels in the blood after a meal, appetite, food intake and the release of hormones in the body, in women with GDM.\n\nPregnant women with GDM, aged 18-50 years old are eligible for the study. Women are not eligible if they have a history of type 1 or 2 diabetes, any clinically confirmed food allergies, taking medication for GDM, severe nausea or using anti-sickness medication.\n\nRecruitment will be via antenatal clinics in the South-Eastern Health and Social Care Trust (SEHSCT). Participants will attend the Centre for Public Health on two occasions (maximum 2 weeks between visits) and will involve the collection of demographic information, weight and height measurements, blood samples, glucose measurements, consumption of study breakfast, and completion of two 1-day food diaries.\n\nParticipants will be asked to eat either the protein/fat-based component of the meal (scrambled egg) before or after the carbohydrate-based component (wholemeal toast) on their first visit and on the other visit they will be asked to eat the meal in the reverse order. The order in which this occurs will be randomised and each participant will act as their own control. Scrambled egg was chosen as the protein and fat will be homogenously distributed (compared to boiled egg, for example). Wholemeal toast was chosen as, although lower glycaemic index and therefore less likely to expeditiously raise blood glucose than toasted white bread, it will be more consistent with the participants' existing dietary needs.""}, 'conditionsModule': {'conditions': ['Gestational Diabetes Mellitus (GDM)'], 'keywords': ['Gestational Diabetes Mellitus', 'Post-prandial glycaemia', 'Food Ordering']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'interventionModelDescription': 'This will be a randomised crossover study. Participants will be asked to eat either the protein/fat-based component of the meal (scrambled egg) before or after the carbohydrate-based component (wholemeal toast) on their first visit and on the other visit they will be asked to eat the meal in the reverse order. The order in which this occurs will be randomised and each participant will act as their own control.', 'primaryPurpose': 'OTHER', 'maskingInfo': {'masking': 'NONE', 'maskingDescription': 'It is not possible to blind participants or researchers in this study due to the nature of the nutritional intervention. However, the allocation to each group will be blinded using envelopes.'}}, 'enrollmentInfo': {'count': 35, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Visit 1: Protein/fat then carbohydrate. Visit 2: Carbohydrate then protein/fat.', 'type': 'EXPERIMENTAL', 'description': 'Participants who are randomised to eat the protein/fat-based component (scrambled egg) of the meal before the carbohydrate-based component (wholemeal toast) on their first study visit and on their second study visit they will be asked to eat the meal in the reverse order. The order in which this occurs will be randomised and each participant will act as their own control.', 'interventionNames': ['Other: Visit 1: Protein/fat then carbohydrate. Visit 2: Carbohydrate then protein/fat.']}, {'label': 'Visit 1: Carbohydrate then protein/fat. Visit 2: Protein/fat then carbohydrate.""', 'type': 'EXPERIMENTAL', 'description': 'Participants who are randomised to eat the carbohydrate-based component (wholemeal toast) of the meal before the protein/fat-based component (scrambled egg) on their first study visit and on their second study visit they will be asked to eat the meal in the reverse order. The order in which this occurs will be randomised and each participant will act as their own control.', 'interventionNames': ['Other: Visit 1: Carbohydrate then protein/fat. Visit 2: Protein/fat then carbohydrate.']}], 'interventions': [{'type': 'OTHER', 'name': 'Visit 1: Protein/fat then carbohydrate. Visit 2: Carbohydrate then protein/fat.', 'description': 'Participants who are randomised to eat the protein/fat-based component (scrambled egg) of the meal before the carbohydrate-based component (wholemeal toast) on their first study visit, will be asked to eat the meal in the reverse order at their second study visit. Meals will be prepared by members of the research team who have completed Food Safety training. Participants will be asked to consume a 440kcal breakfast meal within 10 minutes, approximately 1.5 hours after arrival at their first study visit and approximately 30 minutes after arrival at their second study visit.', 'armGroupLabels': ['Visit 1: Protein/fat then carbohydrate. Visit 2: Carbohydrate then protein/fat.']}, {'type': 'OTHER', 'name': 'Visit 1: Carbohydrate then protein/fat. Visit 2: Protein/fat then carbohydrate.', 'description': 'Participants who are randomised to eat the carbohydrate-based component (wholemeal toast) of the meal before the protein/fat-based component (scrambled egg) on their first study visit, will be asked to eat the meal in the reverse order at their second study visit. Meals will be prepared by members of the research team who have completed Food Safety training. Participants will be asked to consume a 440kcal breakfast meal within 10 minutes, approximately 1.5 hours after arrival at their first study visit and approximately 30 minutes after arrival at their second study visit.', 'armGroupLabels': ['Visit 1: Carbohydrate then protein/fat. Visit 2: Protein/fat then carbohydrate.""']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Postprandial Glucose', 'description': 'The difference in the magnitude of postprandial rise in blood glucose between the two test meals.', 'timeFrame': 'Difference between Visit 1 [time 0 and 125 minutes] and Visit 2 [time 0 and 125 minutes]'}], 'secondaryOutcomes': [{'measure': 'Insulin', 'description': 'The difference in the magnitude of postprandial change in serum levels of insulin between the two test meals.', 'timeFrame': 'Difference between Visit 1 [time 0 and 30 minutes] and Visit 2 [time 0 and 30 minutes]'}, {'measure': 'C-Peptide', 'description': 'The difference in the magnitude of postprandial change in serum levels of c-peptide between the two test meals.', 'timeFrame': 'Difference between Visit 1 [time 0 and 30 minutes] and Visit 2 [time 0 and 30 minutes]'}, {'measure': 'Total Ghrelin', 'description': 'The difference in the magnitude of postprandial change in serum levels of total ghrelin between the two test meals.', 'timeFrame': 'Difference between Visit 1 [time 0 and 30 minutes] and Visit 2 [time 0 and 30 minutes]'}, {'measure': 'Glucagon (GCG)', 'description': 'The difference in the magnitude of postprandial change in serum levels of GCG between the two test meals.', 'timeFrame': 'Difference between Visit 1 [time 0 and 30 minutes] and Visit 2 [time 0 and 30 minutes]'}, {'measure': 'Glucagon-like peptide-1 (GLP-1)', 'description': 'The difference in the magnitude of postprandial change in serum levels of GLP-1 between the two test meals.', 'timeFrame': 'Difference between Visit 1 [time 0 and 30 minutes] and Visit 2 [time 0 and 30 minutes]'}, {'measure': 'Peptide Tyrosine (PYY)', 'description': 'The difference in the magnitude of postprandial change in serum levels of PYY between the two test meals.', 'timeFrame': 'Difference between Visit 1 [time 0 and 30 minutes] and Visit 2 [time 0 and 30 minutes]'}, {'measure': 'Satiety Scores', 'description': 'The difference in mean change in pre-post ingestion satiety scores between the two test meals, using an appetite visual analogue scale (range 0 - 100) \\[The direction of the score will depend on the individual question\\].', 'timeFrame': 'Difference between Visit 1 [time 0 and 30 minutes] and Visit 2 [time 0 and 30 minutes]'}, {'measure': 'Nutrient intake', 'description': 'The difference in 24 hour energy and macronutrient intake following the two test meals.', 'timeFrame': 'Difference between Visit 1 [time 0 and 24 hours] and Visit 2 [time 0 and 24 hours]'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* Pregnant women with gestational diabetes mellitus\n* Aged 18-50 years old\n\nExclusion Criteria:\n\n* History of type 1 or type 2 diabetes mellitus\n* Dietary restrictions or clinically confirmed food allergies that may affect study requirements\n* Pharmacologically managed GDM at the point of study entry\n* Hyperemesis gravidarum at the point of study entry (i.e. prolonged/severe nausea and vomiting)\n* Using antiemetic medication (e.g. dimenhydrinate, prochlorperazine, promethazine)\n* Any other problems or medical conditions that would substantially limit their ability to complete the study requirements\n\nParticipants can be recruited onto the study if they have previously had GDM in another pregnancy. Participants can also be recruited if they are involved in other research studies, but this will depend on the study type and the decision will be made by the Chief/Principal Investigator.', 'healthyVolunteers': False, 'sex': 'FEMALE', 'genderBased': True, 'genderDescription': 'Participants must be pregnant with GDM to take part in the study, and therefore must be female.', 'minimumAge': '18 Years', 'maximumAge': '50 Years', 'stdAges': ['ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Jayne Woodside, PhD', 'role': 'CONTACT', 'phone': '02890 978942', 'email': 'j.woodside@qub.ac.uk'}, {'name': 'Danielle Logan, PhD', 'role': 'CONTACT', 'email': 'd.logan@qub.ac.uk'}], 'overallOfficials': [{'name': 'Jayne Woodside, PhD', 'affiliation': ""Queen's University, Belfast"", 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'Centre for Public Health, Institute of Clinical Sciences A', 'status': 'RECRUITING', 'city': 'Belfast', 'zip': 'BT12 6BA', 'country': 'United Kingdom', 'contacts': [{'name': 'Jayne Woodside, PhD', 'role': 'CONTACT', 'phone': '02890 978942', 'email': 'j.woodside@qub.ac.uk'}, {'name': 'Danielle Logan, PhD', 'role': 'CONTACT', 'email': 'd.logan@qub.ac.uk'}, {'name': 'Jayne Woodside, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'geoPoint': {'lat': 54.59682, 'lon': -5.92541}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'The researchers are happy to share results from the study for the purposes of a meta-analysis. This will be completed on approach to the researchers.', 'infoTypes': ['STUDY_PROTOCOL', 'ICF'], 'timeFrame': 'Data should be available from December 2025 and will be available for 2 years.', 'accessCriteria': 'Use of results in a meta-analysis will be available by contacting the research team.'}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D016640', 'term': 'Diabetes, Gestational'}], 'ancestors': [{'id': 'D011248', 'term': 'Pregnancy Complications'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}}",False,"{'largeDocumentModule': {'largeDocs': [{'typeAbbrev': 'Prot_SAP', 'hasProtocol': True, 'hasSap': True, 'hasIcf': False, 'label': 'Study Protocol and Statistical Analysis Plan', 'date': '2025-02-11', 'uploadDate': '2025-03-24T07:45', 'filename': 'Prot_SAP_000.pdf', 'size': 279120}, {'typeAbbrev': 'ICF', 'hasProtocol': False, 'hasSap': False, 'hasIcf': True, 'label': 'Informed Consent Form', 'date': '2025-02-11', 'uploadDate': '2025-03-04T06:39', 'filename': 'ICF_001.pdf', 'size': 138988}]}}"
"{'identificationModule': {'nctId': 'NCT05023993', 'orgStudyIdInfo': {'id': '20676'}, 'secondaryIdInfos': [{'id': 'NCI-2021-02807', 'type': 'REGISTRY', 'domain': 'CTRP (Clinical Trial Reporting Program)'}, {'id': '20676', 'type': 'OTHER', 'domain': 'City of Hope Medical Center'}, {'id': 'P30CA033572', 'type': 'NIH', 'link': 'https://reporter.nih.gov/quickSearch/P30CA033572'}], 'organization': {'fullName': 'City of Hope Medical Center', 'class': 'OTHER'}, 'briefTitle': 'The Effect of Exercise and Nicotinamide Riboside Muscle Health and Insulin Resistance in Survivors of Childhood Cancer', 'officialTitle': 'The Effect of Exercise and Nicotinamide Riboside on Muscle Health and Insulin Resistance in Adult Survivors of Childhood Cancer With Prediabetes: A Pilot Feasibility Study'}, 'statusModule': {'statusVerifiedDate': '2025-11', 'overallStatus': 'ACTIVE_NOT_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2022-06-23', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-09-21', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-09-21', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2021-08-04', 'studyFirstSubmitQcDate': '2021-08-20', 'studyFirstPostDateStruct': {'date': '2021-08-27', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-11-06', 'lastUpdatePostDateStruct': {'date': '2025-11-07', 'type': 'ESTIMATED'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'SPONSOR'}, 'leadSponsor': {'name': 'City of Hope Medical Center', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Cancer Institute (NCI)', 'class': 'NIH'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'This trial studies the effect of exercise and nicotinamide riboside on muscle health and insulin resistance in adult survivors of childhood cancer with prediabetes (elevated blood sugar level that is not high enough to be considered diabetes). Nicotinamide riboside is a dietary supplement which is similar to vitamin B3. Information collected in this study may help the future development of regimens to improve metabolic outcomes such as muscle health and insulin resistance (when the body is not normally responding to insulin) in childhood cancer survivors.', 'detailedDescription': 'PRIMARY OBJECTIVE:\n\nI. Evaluate the feasibility of conducting a home exercise and nutrition intervention in childhood cancer survivors (CCS) with a history of prediabetes.\n\nEXPLORATORY OBJECTIVES:\n\nI. Describe the association between patient demographics and treatment exposures and subsequent hyperglycemia and skeletal muscle health in childhood cancer survivors.\n\nII. Describe the effect of exercise with or without nicotinamide riboside (NR) on hyperglycemia and skeletal muscle health in CCS with a history of prediabetes.\n\nOUTLINE: Patients are randomized to 1 of 2 arms.\n\nARM I: Patients complete 18 home exercise sessions over 30 minutes each, 3 days per weeks for 6 weeks.\n\nARM II: Patients complete home exercise as in Arm I. Patients also receive nicotinamide riboside orally (PO) daily for 6 weeks.'}, 'conditionsModule': {'conditions': ['Hematopoietic and Lymphoid Cell Neoplasm', 'Malignant Solid Neoplasm', 'Prediabetes']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'SUPPORTIVE_CARE', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 20, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Arm I (home exercise)', 'type': 'ACTIVE_COMPARATOR', 'description': 'Patients complete 18 home exercise sessions over 30 minutes each, 3 days per weeks for 6 weeks.', 'interventionNames': ['Other: Exercise Intervention']}, {'label': 'Arm II (home exercise, nicotinamide riboside)', 'type': 'EXPERIMENTAL', 'description': 'Patients complete home exercise as in Arm I. Patients also receive nicotinamide riboside PO daily for 6 weeks.', 'interventionNames': ['Other: Exercise Intervention', 'Dietary Supplement: Nicotinamide Riboside']}], 'interventions': [{'type': 'OTHER', 'name': 'Exercise Intervention', 'description': 'Complete home exercise', 'armGroupLabels': ['Arm I (home exercise)', 'Arm II (home exercise, nicotinamide riboside)']}, {'type': 'DIETARY_SUPPLEMENT', 'name': 'Nicotinamide Riboside', 'description': 'Given PO', 'armGroupLabels': ['Arm II (home exercise, nicotinamide riboside)'], 'otherNames': ['Niagen', 'NR']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Feasibility of a nutrition and exercise program in childhood cancer survivors (CCS)', 'description': 'The current protocol will be considered feasible if:\n\n1. \\>= 50% of eligible patients that are approached for participation enroll onto the study,\n2. \\>= 70% of enrolled participants successfully complete all study assessments (i.e. physical function tests, blood draw, imaging, and questionnaires at baseline and 6 weeks, and\n3. Enrolled participants demonstrate \\>= 70% compliance with prescribed exercise and nicotinamide riboside.\n\nFeasibility measures 2 and 3 will be assessed for the entire group of 20 subjects as a whole.', 'timeFrame': 'Up to 6 weeks'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* History of childhood cancer\n* History of prediabetes (HbA1c 5.7-6.4%)\n* In remission at time of enrollment\n* Time between completion of cancer-directed therapy and study entry: \\>= 6 months\n* At least 18 years of age at time of enrollment\n* Able to access online exercise program at home\n* Ability to tolerate the prescribed resistance exercise program\n* English-speaking\n* Able to understand and sign the study specific informed consent form (ICF)\n\nExclusion Criteria:\n\n* Taking a nicotinamide adenine dinucleotide (NAD)+ precursor in the two weeks prior to enrollment\n* Currently taking medication for hyperglycemia or diabetes\n* Females who are pregnant or planning to become pregnant\n* Currently recovering from an injury\n* Contraindication to magnetic resonance imaging (MRI)\n* Pacemaker', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Rusha Bhandari', 'affiliation': 'City of Hope Medical Center', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'City of Hope Medical Center', 'city': 'Duarte', 'state': 'California', 'zip': '91010', 'country': 'United States', 'geoPoint': {'lat': 34.13945, 'lon': -117.97729}}]}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D019337', 'term': 'Hematologic Neoplasms'}, {'id': 'D011236', 'term': 'Prediabetic State'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D006402', 'term': 'Hematologic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C018613', 'term': 'nicotinamide-beta-riboside'}]}}",False,
"{'identificationModule': {'nctId': 'NCT03734107', 'orgStudyIdInfo': {'id': '30004426'}, 'organization': {'fullName': ""Children's National Research Institute"", 'class': 'OTHER'}, 'briefTitle': 'Improving Health Communication During the Transition From Pediatric to Adult Diabetes Care', 'officialTitle': 'Improving Health Communication During the Transition From Pediatric to Adult Diabetes Care'}, 'statusModule': {'statusVerifiedDate': '2024-02', 'overallStatus': 'ACTIVE_NOT_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2018-11-06', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-12-01', 'type': 'ACTUAL'}, 'completionDateStruct': {'date': '2024-12-15', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2018-11-01', 'studyFirstSubmitQcDate': '2018-11-06', 'studyFirstPostDateStruct': {'date': '2018-11-07', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-02-05', 'lastUpdatePostDateStruct': {'date': '2024-02-07', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Randi Streisand', 'investigatorTitle': 'Principal Investigator', 'investigatorAffiliation': ""Children's National Research Institute""}, 'leadSponsor': {'name': ""Children's National Research Institute"", 'class': 'OTHER'}, 'collaborators': [{'name': 'American Diabetes Association', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'descriptionModule': {'briefSummary': 'Adolescents and young adults (AYAs; ages 17-23) with type 1 diabetes are at high risk for negative health outcomes, including poor glycemic control and disengagement from the health care system. The deterioration of glycemic control occurs in parallel with the assumption of independent self-care skills and preparation for adult diabetes care. Effective communication between AYAs and health care providers may be a critical contributor to diabetes self-care skills during the transition to adult diabetes care and related glycemic control. This research will attempt to better prepare adolescents and young adults for adult diabetes care by delivering innovative intervention content focused on both health communication skills and transition readiness skills. The investigators aim to leverage innovative technologies to improve developmentally-appropriate communication skills related to planning for clinic visits, disclosing and discussing diabetes-related concerns, and optimizing glucose data review in preparation for adult diabetes care. Adolescents and young adults with type 1 diabetes (ages 17-23) who are planning to transition to adult diabetes care within the next 6-8 months will be enrolled in the study and randomized to either the intervention group or a standard care control group. Medical, communication and psychosocial data (including A1c, glucose monitoring frequency, communication quality, health care engagement, depressive symptoms) will be collected from adolescent and young adult participants and health care providers at baseline and two follow-up time points, approximately 4 months post-baseline and approximately 8-12 months post-baseline after the transfer to adult diabetes care. This intervention has the potential to improve diabetes self-care skills, including engagement with health care providers, and glycemic control in AYAs with type 1 diabetes during the vulnerable period of transfer to adult diabetes care. The results of this work will inform best practices for the transition to adult diabetes care and can be translated into clinical care.', 'detailedDescription': ""Research Design and Methods Overview of Study Design \\& Procedure. The aim of this randomized controlled trial (RCT) is to determine the efficacy of a behavioral intervention targeting health communication skills and diabetes self-management skills in preparation for the transfer to adult diabetes care, compared to usual care. The intervention, Plan, Reflect, and Engage with Providers for Diabetes Care (PREP-DC), consists of three intervention sessions with a study interventionist, paired text messages, and access to glucose management software. It is expected that adolescents and young adults allocated to the intervention condition (PREP-DC) will evidence: 1) better glycemic control (lower A1c); 2) shorter gap in time between the last visit in pediatric diabetes care and the first visit in adult diabetes care; 3) better diabetes management (better adherence to the diabetes regimen); 4) fewer reported complications (e.g. hospitalizations and emergency department visits). A total of 100 adolescent and young adult participants (ages 17-23) will be randomly allocated in a 1:1 ratio to either the PREP-DC intervention condition (n=50) or usual care (n=50; standard care comparison condition): all participants receive standard resources for transition to adult diabetes care as part of usual care in both conditions.\n\nParticipants include 100 adolescents and young adults (ages 17-23) diagnosed with T1D for at least one year (anticipated 50% female) seen for diabetes care at Children's National Medical Center (CNMC) in Washington, DC. Eligible participants will self-identify as planning to transfer to adult diabetes care within the upcoming 6-8 months. Participants in the PREP-DC intervention will complete three intervention sessions with study team members over a 3 month period (approximately 1 intervention session per month). Two sessions will be with a trained study interventionist focusing on communication with health care providers and preparation for medical visits and adult diabetes care. One session will be with a certified diabetes education focusing on problem-solving using glucose data and glucose data review. PREP-DC intervention participants will also receive text messages (3-4 messages/week) for the 3 month intervention period supporting intervention content. Participants also will be given information about accessing glucose management software specific to their diabetes devices and related study resources (e.g. study website). Participants are evaluated at baseline (pre-randomization to intervention or standard care comparison group) and follow-up (approximately 4 months post-baseline and approximately 8-12 months post-baseline after the transition to adult diabetes care).""}, 'conditionsModule': {'conditions': ['Type 1 Diabetes Mellitus'], 'keywords': ['transition to adult medical care', 'adolescents and young adults', 'health communication', 'adherence', 'type 1 diabetes']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Participants are randomized in a 1:1 ratio to the intervention group or standard care comparison group', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 52, 'type': 'ACTUAL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'PREP-DC Intervention', 'type': 'EXPERIMENTAL', 'description': '50 participants will be randomized to the Plan, Reflect, and Engage with Providers for Diabetes Care (PREP-DC) intervention. Participants will complete 3 intervention sessions with study interventionists and will receive text messages and other study resources during the active intervention period (3 months).', 'interventionNames': ['Behavioral: Plan, Reflect, and Engage with Providers for Diabetes Care']}, {'label': 'Standard Care Comparison', 'type': 'NO_INTERVENTION', 'description': '50 participants will be randomized to standard care and will participate in regular diabetes clinic visits and receive standard materials on the transition to adult diabetes care, as they would have done without participation in this study.'}], 'interventions': [{'type': 'BEHAVIORAL', 'name': 'Plan, Reflect, and Engage with Providers for Diabetes Care', 'description': 'Behavioral intervention designed to improve health communication skills and readiness for adult diabetes care', 'armGroupLabels': ['PREP-DC Intervention'], 'otherNames': ['PREP-DC']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Hemoglobin A1c', 'description': 'measurement of hemoglobin A1c (A1c; reported as a percentage)', 'timeFrame': '8 months post-baseline'}, {'measure': 'Number of days to first adult diabetes care visit', 'description': 'Number of days between the last visit in pediatric diabetes care and the first visit in adult diabetes care (reported as number of days)', 'timeFrame': '8 months post-baseline'}, {'measure': 'Adherence to the diabetes care regimen', 'description': 'Participant report on the Diabetes Management Questionnaire (DMQ), a self-report measure of adherence to the diabetes care regimen. The DMQ consists of 20 items scored on a 0-4 Likert Scale. The measure has a total score; the mean score on all items is calculated and multiplied by 25 to arrive at the total score (possible range 0-100). A higher score indicates greater adherence to diabetes management.', 'timeFrame': '8 months post-baseline'}, {'measure': 'Diabetes-related hospitalizations', 'description': 'Participant report and medical record review of reported diabetes-related hospitalizations for the duration of the study period. The total number of hospitalizations is summed.', 'timeFrame': '8 months post-baseline'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* Diagnosed with type1 diabetes for ≥ 1 year\n* Able to adequately understand, speak, and read English to benefit from participation\n* Ready and consistent text messaging access to participate\n* Within 6-8 months of planned transfer to adult diabetes care\n\nExclusion Criteria:\n\n* Other life-threatening disease (e.g. cancer) or major psychiatric disorder (e.g. schizophrenia) that significantly limits participation\n* Pervasive developmental disorder that significantly limits participation', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '17 Years', 'maximumAge': '23 Years', 'stdAges': ['CHILD', 'ADULT']}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Randi Streisand, PhD', 'affiliation': ""Children's National Research Institute"", 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': ""Children's National Health System"", 'city': 'Washington D.C.', 'state': 'District of Columbia', 'zip': '20010', 'country': 'United States', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}]}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003922', 'term': 'Diabetes Mellitus, Type 1'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}}",False,
"{'identificationModule': {'nctId': 'NCT05855863', 'orgStudyIdInfo': {'id': 'GKT'}, 'organization': {'fullName': ""Shanghai 10th People's Hospital"", 'class': 'OTHER'}, 'briefTitle': 'Clinical Study of GKT in Diabetes Related Dementia', 'officialTitle': 'Clinical Study of Ginkgo Biloba Ketone Ester Tablets in Diabetes Related Dementia'}, 'statusModule': {'statusVerifiedDate': '2023-11', 'overallStatus': 'NOT_YET_RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2023-12-01', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2026-06-30', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2026-06-30', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2023-04-10', 'studyFirstSubmitQcDate': '2023-05-02', 'studyFirstPostDateStruct': {'date': '2023-05-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-11-09', 'lastUpdatePostDateStruct': {'date': '2023-11-13', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Guoxiang Fu', 'investigatorTitle': 'Professor', 'investigatorAffiliation': ""Shanghai 10th People's Hospital""}, 'leadSponsor': {'name': ""Shanghai 10th People's Hospital"", 'class': 'OTHER'}}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'Recently a new clinical dementia subgroup based on brain imaging, called ""diabetes related dementia (DrD)"". DrD, unlike Alzheimer\'s disease and vascular dementia, is considered a ""controllable"" or ""modifiable"" form of dementia. However, there is currently a lack of corresponding treatment measures. Ginkgo biloba ketone ester tablets are extracts of Ginkgo biloba leaves. Previous studies have shown that they can increase cerebral blood flow, reduce cerebrovascular resistance, improve cerebral circulation, and are beneficial for the treatment of cognitive impairment. This project intends to explore the role of ginkgo ketoester tablets in diabetes related dementia through a multicenter randomized double-blind controlled clinical study.', 'detailedDescription': ""This study was divided into two treatment groups: the experimental group and the control group. 370 type 2 diabetes patients with mild cognitive impairmentpatients were randomly selected and assigned to the experimental group of 185 patients and the control group of 185 patients in a 1:1 equal amount. Experimental group: Ginkgo biloba ketone ester tablets combined with conventional hypoglycemic treatment group, the usage is Ginkgo biloba ketone ester tablets (Styron), taken orally, 3 times a day, 0.5g each time, and continuously administered for 6 months. Control group: conventional hypoglycemic treatment group. The Montreal Cognitive Assessment Basic (MoCA-B) was used for the detection of cognitive dysfunction. Neuropsychological testing of cognitive function was conducted using Alzheimer's Disease Assessment Scale - Cognitive Scale (ADAS-cog), Auditory Word Learning Test (AVLT-H);Assessment of Daily Living Ability - Functional Activity Questionnaire (FAQ);Shape Connection Test A and B and Symbolic Digital Form Test (SDMT).Collect patients' blood, and detect C-reactive protein, interleukin-6, oxidative stress, ApoE4 genotype, phosphorylated tau protein, irisin, β- Amyloid protein before and after the experiment.Detect changes in ankle brachial pulse wave conduction velocity (baPWV)/and ankle brachial blood pressure index (ABI) of patients before and after the experiment.""}, 'conditionsModule': {'conditions': ['Dementia']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 370, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Ginkgo Ketone Ester Tablets Treatment Group', 'type': 'EXPERIMENTAL', 'description': 'Ginkgo Ketone Ester Tablets (Styron), taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic therapy continuously administered for 6 months', 'interventionNames': ['Drug: Ginkgo Ketone Ester Tablets']}, {'label': 'control group', 'type': 'PLACEBO_COMPARATOR', 'description': 'placebo combined with conventional hypoglycemic therapy for 6 months', 'interventionNames': ['Drug: placebo']}], 'interventions': [{'type': 'DRUG', 'name': 'Ginkgo Ketone Ester Tablets', 'description': 'Ginkgo Ketone Ester Tablets taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic treatment for six months', 'armGroupLabels': ['Ginkgo Ketone Ester Tablets Treatment Group'], 'otherNames': ['Test group']}, {'type': 'DRUG', 'name': 'placebo', 'description': 'placebo, taken orally, 3 times a day, 0.5g each time, combined with conventional hypoglycemic treatment for six months', 'armGroupLabels': ['control group'], 'otherNames': ['Control group']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Cognitive function testing', 'description': ""Alzheimer's Disease Assessment Scale-Cognitive section (0-70), the higher the score, the more severe the cognitive impairment"", 'timeFrame': 'six months'}], 'secondaryOutcomes': [{'measure': 'Memory function assessment', 'description': 'Auditory Word Learning Test (AVLT-H),the lower the score, the more severe the cognitive impairment', 'timeFrame': 'six months'}, {'measure': 'Assessment of daily living ability', 'description': 'Functional Activity Questionnaire (FAQ)S,the higher the score, the more severe the cognitive impairment', 'timeFrame': 'six months'}, {'measure': 'Perform functional evaluation', 'description': 'Shape Connection Test A and B (STT-A\\&B)，the higher the score, the more severe the cognitive impairment', 'timeFrame': 'six months'}, {'measure': 'Attention assessment', 'description': 'Symbolic Digital Form Test (SDMT)，the lower the score, the more severe the cognitive impairment', 'timeFrame': 'six months'}], 'otherOutcomes': [{'measure': 'Concentration of C-reactive protein', 'description': 'Human CRP(C-Reactive Protein) ELISA Kit for detecting C-reactive protein concentration (mg/L )in serum', 'timeFrame': 'six months'}, {'measure': 'Rate of arteriosclerosis in the large and middle arterial systems', 'description': 'ankle brachial pulse wave conduction velocity (m/s )detected by Arteriosclerosis tester', 'timeFrame': 'six months'}, {'measure': 'Rate of arterial blockage in limbs', 'description': 'ankle brachial blood pressure index (ABI) measures ankle blood pressure and upper arm brachial artery blood pressure through ankle brachial index instrument', 'timeFrame': 'six months'}, {'measure': 'Concentration of interleukin-6', 'description': 'interleukin-6(IL-6) in serum detected by interleukin-6 ELISA Kit', 'timeFrame': 'six months'}, {'measure': 'Concentration of phosphorylation (p) - tau217', 'description': 'Plasma phosphorylation (p) - tau217detected by P-Tau217 detection kit', 'timeFrame': 'six months'}, {'measure': 'Concentration of Amyloid protein Aβ 42/40', 'description': 'Plasma Amyloid protein Aβ 42/40 detected by Aβ 42/40 detection kit', 'timeFrame': 'six months'}, {'measure': 'Participants with ApoE4 genotype', 'description': 'ApoE4 genotype detected by ApoE4 genotype kit', 'timeFrame': 'six months'}, {'measure': 'Concentration of antioxidant enzyme activity', 'description': 'Detection of glutathione peroxidase in serum', 'timeFrame': 'six months'}, {'measure': 'Concentration of oxidative stress', 'description': 'Free radical detection in serum', 'timeFrame': 'six months'}, {'measure': 'Concentration of irisin', 'description': 'Plasma irisin concentration detected by irisin ELISA kit', 'timeFrame': 'six months'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Type 2 diabetes with mild cognitive impairment patients aged 65 years or above;\n2. Able to cooperate in completing cognitive function testing;\n3. Patients who can swallow pills\n4. No previous history of stroke，cerebral thrombosis, etc\n\nExclusion Criteria:\n\n1. Type 1 diabetes;\n2. Acute cerebral infarction and myocardial infarction within 3 months;\n3. Severe liver and kidney dysfunction;\n4. Late stage malignant tumors;\n5. Thyroid dysfunction；\n6. Brain injury and cerebral hemorrhage within 3 months；\n7. Folic acid and/or vitamin B12 deficiency\n8. Patients who are currently using thrombin inhibitors, defibrillators (with unclear efficacy in ischemic stroke and increased risk of bleeding), antiplatelet drugs, blood activating and stasis resolving agents, and other ginkgo biloba leaf preparations (as they may affect the evaluation of the therapeutic effect of ginkgo biloba ester tablets in this trial), as well as other trial medications.', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '60 Years', 'maximumAge': '90 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'referencesModule': {'references': [{'pmid': '23594859', 'type': 'RESULT', 'citation': ""Fukazawa R, Hanyu H, Sato T, Shimizu S, Koyama S, Kanetaka H, Sakurai H, Iwamoto T. Subgroups of Alzheimer's disease associated with diabetes mellitus based on brain imaging. Dement Geriatr Cogn Disord. 2013;35(5-6):280-90. doi: 10.1159/000348407. Epub 2013 Apr 13.""}, {'pmid': '26289708', 'type': 'RESULT', 'citation': 'Hanyu H, Hirose D, Fukasawa R, Hatanaka H, Namioka N, Sakurai H. Guidelines for the Clinical Diagnosis of Diabetes Mellitus-Related Dementia. J Am Geriatr Soc. 2015 Aug;63(8):1721-3. doi: 10.1111/jgs.13581. No abstract available.'}, {'pmid': '25926349', 'type': 'RESULT', 'citation': 'Verdile G, Fuller SJ, Martins RN. The role of type 2 diabetes in neurodegeneration. Neurobiol Dis. 2015 Dec;84:22-38. doi: 10.1016/j.nbd.2015.04.008. Epub 2015 Apr 26.'}, {'pmid': '24405824', 'type': 'RESULT', 'citation': 'Fukasawa R, Hanyu H, Namioka N, Hatanaka H, Sato T, Sakurai H. Elevated inflammatory markers in diabetes-related dementia. Geriatr Gerontol Int. 2014 Jan;14(1):229-31. doi: 10.1111/ggi.12140. No abstract available.'}, {'pmid': '26531676', 'type': 'RESULT', 'citation': 'Hatanaka H, Hanyu H, Fukasawa R, Sato T, Shimizu S, Sakurai H. Peripheral oxidative stress markers in diabetes-related dementia. Geriatr Gerontol Int. 2016 Dec;16(12):1312-1318. doi: 10.1111/ggi.12645. Epub 2015 Nov 4.'}, {'pmid': '27109174', 'type': 'RESULT', 'citation': 'Hirose D, Hanyu H, Fukasawa R, Hatanaka H, Namioka N, Sakurai H. Frailty in diabetes-related dementia. Geriatr Gerontol Int. 2016 May;16(5):653-5. doi: 10.1111/ggi.12566. No abstract available.'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}}","{'miscInfoModule': {'versionHolder': '2026-01-02'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003704', 'term': 'Dementia'}], 'ancestors': [{'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D019965', 'term': 'Neurocognitive Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D035061', 'term': 'Control Groups'}], 'ancestors': [{'id': 'D015340', 'term': 'Epidemiologic Research Design'}, {'id': 'D004812', 'term': 'Epidemiologic Methods'}, {'id': 'D008919', 'term': 'Investigative Techniques'}, {'id': 'D012107', 'term': 'Research Design'}, {'id': 'D008722', 'term': 'Methods'}]}}",False,
"{'identificationModule': {'nctId': 'NCT06579404', 'orgStudyIdInfo': {'id': 'COYOTE'}, 'organization': {'fullName': 'University of Cambridge', 'class': 'OTHER'}, 'briefTitle': 'Closed-loop in Adults With Type 2 Diabetes', 'officialTitle': 'An Open-label, Multinational, Multicentre, Randomised, Single-period Parallel Study to Assess the Efficacy, Safety and Utility of Fully Closed-loop Insulin Delivery Compared to Standard Insulin Therapy With CGM in Adults With Type 2 Diabetes', 'acronym': 'COYOTE'}, 'statusModule': {'statusVerifiedDate': '2025-07', 'overallStatus': 'RECRUITING', 'expandedAccessInfo': {'hasExpandedAccess': False}, 'startDateStruct': {'date': '2024-12-06', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-03', 'type': 'ESTIMATED'}, 'completionDateStruct': {'date': '2027-07', 'type': 'ESTIMATED'}, 'studyFirstSubmitDate': '2024-08-16', 'studyFirstSubmitQcDate': '2024-08-27', 'studyFirstPostDateStruct': {'date': '2024-08-30', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-07-18', 'lastUpdatePostDateStruct': {'date': '2025-07-23', 'type': 'ACTUAL'}}, 'sponsorCollaboratorsModule': {'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorFullName': 'Dr Roman Hovorka', 'investigatorTitle': 'Professor of Metabolic Technology', 'investigatorAffiliation': 'University of Cambridge'}, 'leadSponsor': {'name': 'University of Cambridge', 'class': 'OTHER'}, 'collaborators': [{'name': 'University of Edinburgh', 'class': 'OTHER'}, {'name': 'Jaeb Center for Health Research', 'class': 'OTHER'}, {'name': 'Swansea University', 'class': 'OTHER'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False, 'isUsExport': False}, 'descriptionModule': {'briefSummary': 'The main objective of this study is to determine the efficacy, safety and utility of fully closed-loop glucose control in the home setting in adults with type 2 diabetes (T2D). This study builds on previous and on-going studies of closed-loop systems that have been performed in Cambridge in adults with type 2 diabetes in the inpatient and in the home setting and in children and adults with type 1 diabetes.\n\nThis is an open-label, multi-national, multi-centre, randomised, single-period parallel study, involving a run-in period followed by a 26-week intervention period during which glucose levels will be controlled either by a fully closed-loop system or by participants usual insulin therapy with continuous glucose monitoring. A total of up to 224 adults with type 2 diabetes using insulin will be recruited through outpatient diabetes clinics, primary care centres, social media advertising and other established methods at participating centres. Participants will receive appropriate training in the safe use of the study devices.\n\nThe primary outcome is the between group difference in HbA1c at 26 weeks. Other key outcomes include the time spent with glucose levels within, above and below the target glucose range (3.9-10.0mmol/L) and mean sensor glucose as recorded by CGM over the 26 weeks. Insulin requirements, body weight, renal and liver function will also be compared. Safety evaluation comprises severe hypoglycaemic episodes, and other adverse and serious adverse events. Human factors outcomes include CGM \\& closed-loop usage, questionnaires and semi-structured interviews.', 'detailedDescription': ""Purpose of clinical trial:\n\nTo determine the efficacy, safety and utility of fully closed-loop insulin delivery over 26 weeks in the home setting in adults with type 2 diabetes.\n\nStudy objectives:\n\nTo determine the efficacy, safety and utility of fully closed-loop insulin delivery over 26 weeks in the home setting in adults with type 2 diabetes.\n\n1. EFFICACY: The objective is to assess the ability of fully closed-loop insulin delivery to improve glucose control as measured by HbA1c (primary endpoint) and sensor glucose metrics.\n2. SAFETY: The objective is to evaluate the safety of fully closed-loop insulin delivery in terms of episodes and severity of hypoglycaemia, and nature and severity of other adverse events.\n3. UTILITY: The objective is to determine the acceptability and duration of use of the CGM and closed-loop system.\n4. HUMAN FACTORS: The objective is to assess cognitive, emotional, and behavioural characteristics of participants and their response to the closed-loop system using validated questionnaires and semi-structured interviews.\n\n   Participating clinical centres:\n\n   UK - Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust. - Imperial College Healthcare NHS Trust, London\n\n   \\- Manchester Royal Infirmary, Manchester University NHS Foundation Trust\n\n   \\- King's College Hospital, King's College Hospital NHS Foundation Trust, London\n\n   \\- Guy's and St Thomas' NHS Foundation Trust\n\n   \\- Norfolk and Norwich University Hospital, Norfolk and Norwich University Hospitals NHS Foundation Trust\n\n   \\- University Hospitals of Leicester NHS Trust\n\n   Switzerland\n\n   \\- Inselspital, Bern University Hospital, Bern\n\n   France\n\n   \\- Centre Hospitalier Universitaire (CHU) de Toulouse\n\n   Germany\n\n   \\- Medical Center - University of Freiburg\n\n   Austria\n\n   \\- Medical University of Graz, Graz\n\n   Czech Republic\n\n   \\- Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague\n\n   Sample Size:\n\n224 participants (112 per group) will be randomised. Recruitment will target a minimum quota of 25% of participants using basal insulin and a minimum quota of 60% of participants using multiple daily insulin injections.\n\nMaximum duration of study for a subject: 30 weeks\n\nRecruitment:\n\nParticipants will be recruited through outpatient diabetes clinics, primary care centres, social media advertising or other established methods at participating centres\n\nConsent:\n\nParticipants will be asked to provide written informed consent.\n\nBaseline Assessment:\n\nEligible participants will undergo baseline evaluation involving talking a medical history including demographics, height/weight, waist hip ratio and blood pressure measurement and blood samples for HbA1c, fasted lipid profile, renal and liver function. A urine albumin-creatinine ratio (ACR) will be performed, along with a urine pregnancy test in females of child-bearing age. Human factors questionnaires will be completed and a masked glucose sensor will be applied.\n\nRun-in Period:\n\nDuring a 2-3 week run-in period, participants will use their usual insulin therapy and wear a masked CGM system. At the end of the run-in period, for compliance, at least 10 days of CGM data needs to be recorded. CGM data during the run-in period will be used to assess baseline glucose control before the start of the intervention phase.\n\nRandomisation:\n\nEligible participants will be randomised in a 1:1 ratio using central randomisation software to fully closed-loop or standard insulin therapy with CGM for 26 weeks. Randomisation will be stratified by site and baseline HbA1c.\n\nFully closed loop insulin delivery (intervention arm):\n\nFollowing randomisation, participants in the closed-loop group will receive training on the study CGM, study insulin pump and closed-loop App during a 1-2 hour outpatient session. Competency on the use of the closed-loop system will be evaluated. Further training may be delivered as required. Participants will be advised to use the closed-loop system for the next 26 weeks.\n\nStandard insulin therapy with CGM (control arm):\n\nFollowing randomisation, participants in the control group will use their usual insulin therapy and the study CGM. Training on the use of the CGM will be provided. Participants will use standard insulin therapy and CGM for the next 26 weeks.\n\n3 month study visit: Weight, waist hip ratio and blood pressure will be measured and a blood sample will be taken for measurement of HbA1c, fasted lipid profile, renal and liver function. Data from the closed-loop system and CGM system will be reviewed. Human factors questionnaires will be completed.\n\nEnd of study assessments:\n\nWeight, waist hip ratio and blood pressure will be measured and a blood sample will be taken for measurement of HbA1c, fasted lipid profile, renal and liver function. Urinary ACR will be measured. Human factors questionnaires will be completed and a subset of participants will participate in interviews. Study devices will be returned and participants will resume their usual insulin therapy and standard glucose monitoring.\n\nProcedures for safety monitoring during trial:\n\nStandard operating procedures for monitoring and reporting of all adverse events and adverse device events will be in place, including serious adverse events (SAE), serious adverse device effects (SADE) and specific adverse events (AE) such as severe hypoglycaemia.\n\nA data safety and monitoring board (DSMB) will be informed of all serious adverse events and any unanticipated serious adverse device effects that occur during the study and will review compiled adverse event data at periodic intervals.\n\nCriteria for withdrawal of subjects on safety grounds:\n\nA participant may terminate participation in the study at any time without necessarily giving a reason and without any personal disadvantage. An investigator can stop the participation of a subject after consideration of the benefit/risk ratio. Possible reasons are:\n\n* Participant is unable to demonstrate safe use of study devices as judged by the investigator\n* Serious adverse events\n* Significant protocol violation or non-compliance\n* Decision by the investigator, or the Sponsor, that termination is in the participant's best medical interest\n* Pregnancy, planned pregnancy, or breast feeding\n* Allergic reaction to insulin or severe allergic reaction to adhesive surface of infusion set or glucose sensor\n* Technical grounds (e.g. participant relocates)""}, 'conditionsModule': {'conditions': ['Type 2 Diabetes Treated With Insulin'], 'keywords': ['Closed-loop insulin delivery', 'Type 2 diabetes']}, 'designModule': {'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'A multicentre, multinational, open-label, randomised single period, parallel design study contrasting fully closed-loop insulin delivery and standard insulin therapy with CGM over 26 weeks in adults with type 2 diabetes.', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 224, 'type': 'ESTIMATED'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Fully closed-loop insulin delivery (CamAPS HX)', 'type': 'EXPERIMENTAL', 'description': 'The automated closed loop system (CamAPS FX) will consist of:\n\n* YpsoPump insulin pump (Ypsomed, Burgdorf, Switzerland)\n* FreeStyle Libre 3 glucose sensor (Abbott Diabetes Care, CA, USA)\n* Smartphone hosting CamAPS HX app with the Cambridge model predictive control algorithm\n* Cloud upload system to review CGM/insulin data.\n\nParticipants will use the fully closed-loop system for 26 weeks at home', 'interventionNames': ['Device: CamAPS HX']}, {'label': 'Standard insulin therapy with glucose sensor', 'type': 'ACTIVE_COMPARATOR', 'description': 'Usual insulin therapy and FreeStyle Libre 3 glucose sensor (Abbott Diabetes Care, CA, USA) for 26 weeks at home.', 'interventionNames': ['Other: Standard insulin therapy with glucose sensor']}], 'interventions': [{'type': 'DEVICE', 'name': 'CamAPS HX', 'description': 'The automated closed loop system (CamAPS HX) will consist of:\n\nYpsoPump insulin pump Freestyle Libre 3 glucose sensor Smartphone hosting CamAPS HX app with the Cambridge model predictive control algorithm', 'armGroupLabels': ['Fully closed-loop insulin delivery (CamAPS HX)']}, {'type': 'OTHER', 'name': 'Standard insulin therapy with glucose sensor', 'description': 'Participants usual insulin therapy with Freestyle Libre 3 glucose sensor', 'armGroupLabels': ['Standard insulin therapy with glucose sensor']}]}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Glycated haemoglobin (HbA1c) at 26 weeks', 'description': 'Centralised measurement of HbA1c', 'timeFrame': 'at 26 weeks'}], 'secondaryOutcomes': [{'measure': 'Proportion of time spent in target glucose range (3.9 to 10.0mmol/L)', 'description': 'Sensor glucose metric measured as a %', 'timeFrame': 'over 26 weeks'}, {'measure': 'Mean glucose (mmol/L)', 'description': 'Sensor glucose metric measured in mmol/L', 'timeFrame': 'over 26 weeks'}, {'measure': 'Proportion of time spent above target glucose (>10.0mmol/l)', 'description': 'Sensor glucose metric measured as a %', 'timeFrame': 'over 26 weeks'}, {'measure': 'Proportion of time spent below target glucose (<3.9mmol/L)', 'description': 'Sensor glucose metric measured as a %', 'timeFrame': 'over 26 weeks'}, {'measure': 'Standard deviation of sensor glucose', 'description': 'Sensor glucose metric measured in mmol/L', 'timeFrame': 'over 26 weeks'}, {'measure': 'Coefficient of variation of sensor glucose', 'description': 'Sensor glucose metric measured as a %', 'timeFrame': 'over 26 weeks'}, {'measure': 'Proportion of time spent below target glucose (<3.5mmol/L)', 'description': 'Sensor glucose metric measured as a %', 'timeFrame': 'over 26 weeks'}, {'measure': 'Proportion of time spent below target glucose (<3.0mmol/L)', 'description': 'Sensor glucose metric measured as a %', 'timeFrame': 'over 26 weeks'}, {'measure': 'Proportion of time spent above target glucose (>13.9mmol/l)', 'description': 'Sensor glucose metric measured as a %', 'timeFrame': 'over 26 weeks'}, {'measure': 'Proportion of time spent above target glucose (>16.7mmol/l)', 'description': 'Sensor glucose metric measured as a %', 'timeFrame': 'over 26 weeks'}, {'measure': 'Proportion of time spent above target glucose (>20.0mmol/l)', 'description': 'Sensor glucose metric measured as a %', 'timeFrame': 'over 26 weeks'}, {'measure': 'Proportion of participants with HbA1c <7.0% [53mmol/mol] (%)', 'description': 'Binary metric of HbA1c', 'timeFrame': 'at 26 weeks'}, {'measure': 'Proportion of participants with HbA1c <7.5% [58mmol/mol] (%)', 'description': 'Binary metric of HbA1c', 'timeFrame': 'at 26 weeks'}, {'measure': 'Total daily insulin dose', 'description': 'Measured in units/day', 'timeFrame': 'over 26 weeks'}, {'measure': 'Body weight', 'description': 'Measured in kilograms', 'timeFrame': 'at 26 weeks'}, {'measure': 'Waist hip ratio', 'description': 'Ratio', 'timeFrame': '26 weeks'}, {'measure': 'Body Mass Index (BMI)', 'description': 'Measured in kg/m2', 'timeFrame': '26 weeks'}, {'measure': 'Fasted lipid profile', 'description': 'Measured in mmol/L', 'timeFrame': '26 weeks'}, {'measure': 'Renal function', 'description': 'Renal function as measured by serum creatinine', 'timeFrame': '26 weeks'}, {'measure': 'Renal function', 'description': 'Renal function as measured by estimated Glomerular Filtration Rate', 'timeFrame': '26 weeks'}, {'measure': 'Renal function', 'description': 'Renal function as measured by urinary albumin creatinine ratio', 'timeFrame': '26 weeks'}, {'measure': 'Liver function', 'description': 'Liver function as measured by FIB4 index', 'timeFrame': '26 weeks'}, {'measure': 'Liver function', 'description': 'Liver function as measured by alanine transaminase (ALT)', 'timeFrame': '26 weeks'}, {'measure': 'Liver function', 'description': 'Liver function as measured by aspartate transaminase (AST)', 'timeFrame': '26 weeks'}, {'measure': 'Liver function', 'description': 'Liver function as measured by alkaline phosphatase (ALP)', 'timeFrame': '26 weeks'}, {'measure': 'Liver function', 'description': 'Liver function as measured by gamma-glutamyl transferase (yGT)', 'timeFrame': '26 weeks'}, {'measure': 'Liver function', 'description': 'Liver function as measured by serum bilirubin', 'timeFrame': '26 weeks'}, {'measure': 'Liver function', 'description': 'Liver function as measured by albumin and FIB4 index', 'timeFrame': '26 weeks'}]}, 'eligibilityModule': {'eligibilityCriteria': 'Inclusion Criteria:\n\n* Aged 18 years and older\n* Type 2 diabetes diagnosed for at least 12 months\n* Established on an SGLT2 inhibitor and/or GLP-1 receptor agonist for at least 3 months, or have been offered these therapies previously.\n* Treatment with insulin therapy for at least 6 months\n* HbA1c ≤ 15% (140 mmol/mol) analysis from local laboratory or equivalent\n* Willing to wear study devices and follow study instructions\n* Capacity to consent to participate in the study\n\nExclusion Criteria:\n\n* Type 1 diabetes\n* Current use of insulin pump\n* Current use of any closed-loop system\n* Any physical/psychological disease or medication(s) likely to interfere with the conduct of the study and interpretation of the study results, as judged by study clinician\n* Known or suspected allergy against insulin\n* Medically documented allergy towards the adhesive\n* Pregnancy, planned pregnancy, or breast feeding\n* Severe visual impairment\n* Severe hearing impairment\n* Medically documented allergy towards the adhesive (glue) of plasters\n* Serious skin diseases located at places of the body, which potentially are possible to be used for localisation of the glucose sensor\n* Illicit drugs abuse\n* Prescription drugs abuse\n* Alcohol abuse', 'healthyVolunteers': False, 'sex': 'ALL', 'minimumAge': '18 Years', 'stdAges': ['ADULT', 'OLDER_ADULT']}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Charlotte K Boughton, PhD', 'role': 'CONTACT', 'phone': '+44 (0)1223 769066', 'email': 'cb2000@medschl.cam.ac.uk'}, {'name': 'Angel Tseung', 'role': 'CONTACT', 'email': 'ftt20@cam.ac.uk'}], 'overallOfficials': [{'name': 'Roman Hovorka', 'affiliation': 'University of Cambridge', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'locations': [{'facility': 'University of Melbourne', 'status': 'NOT_YET_RECRUITING', 'city': 'Melbourne', 'country': 'Australia', 'contacts': [{'name': ""David O'Neal"", 'role': 'CONTACT'}], 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}, {'facility': 'Medical University of Graz', 'status': 'NOT_YET_RECRUITING', 'city': 'Graz', 'country': 'Austria', 'contacts': [{'name': 'Julia Mader', 'role': 'CONTACT'}], 'geoPoint': {'lat': 47.06733, 'lon': 15.44197}}, {'facility': 'Diabetes Centre, Institute of Clinical and Experimental Medicine', 'status': 'NOT_YET_RECRUITING', 'city': 'Prague', 'country': 'Czechia', 'contacts': [{'name': 'Martin Haluzík', 'role': 'CONTACT'}], 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'facility': 'CHU de Toulouse', 'status': 'NOT_YET_RECRUITING', 'city': 'Toulouse', 'country': 'France', 'contacts': [{'name': 'Hélène Hanaire', 'role': 'CONTACT'}], 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'facility': 'Bern University Hospital', 'status': 'NOT_YET_RECRUITING', 'city': 'Bern', 'country': 'Switzerland', 'contacts': [{'name': 'Lia Bally', 'role': 'CONTACT'}], 'geoPoint': {'lat': 46.94809, 'lon': 7.44744}}, {'facility': ""Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust"", 'status': 'RECRUITING', 'city': 'Cambridge', 'country': 'United Kingdom', 'contacts': [{'name': 'Charlotte Boughton', 'role': 'CONTACT'}], 'geoPoint': {'lat': 52.2, 'lon': 0.11667}}, {'facility': 'Royal Derby Hospital', 'status': 'NOT_YET_RECRUITING', 'city': 'Derby', 'country': 'United Kingdom', 'contacts': [{'name': 'Emma Wilmot', 'role': 'CONTACT'}], 'geoPoint': {'lat': 52.92277, 'lon': -1.47663}}, {'facility': 'Leicester Diabetes Centre', 'status': 'RECRUITING', 'city': 'Leicester', 'country': 'United Kingdom', 'contacts': [{'name': 'Pratik Choudhary', 'role': 'CONTACT'}], 'geoPoint': {'lat': 52.6386, 'lon': -1.13169}}, {'facility': ""Guy's and St Thomas' NHS Foundation Trust"", 'status': 'RECRUITING', 'city': 'London', 'country': 'United Kingdom', 'contacts': [{'name': 'Sufyan Hussain', 'role': 'CONTACT'}], 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'facility': ""King's College Hospital, King's College NHS Foundation Trust"", 'status': 'RECRUITING', 'city': 'London', 'country': 'United Kingdom', 'contacts': [{'name': 'Yee Cheah', 'role': 'CONTACT'}], 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'facility': 'Manchester Royal Infirmary, Central Manchester University Hospitals NHS Foundation Trust', 'status': 'NOT_YET_RECRUITING', 'city': 'Manchester', 'country': 'United Kingdom', 'contacts': [{'name': 'Hood Thabit', 'role': 'CONTACT'}], 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}, {'facility': 'Norfolk and Norwich University Hospital', 'status': 'RECRUITING', 'city': 'Norwich', 'country': 'United Kingdom', 'contacts': [{'name': 'Sankalpa Neupane', 'role': 'CONTACT'}], 'geoPoint': {'lat': 52.62783, 'lon': 1.29834}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': 'Study protocol, statistical analysis plan and fully anonymised individual participant data that underlie the results reported in the manuscript will be available 6 months following publication and ending 36 months following manuscript publication to investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose, to achieve aims in the approved proposal. Proposals should be directed to rh347@cam.ac.uk and may be submitted up to 36 months following article publication. To gain access, data requestors will need to sign a data access agreement.\n\nFully anonymised data may be shared with third parties (EU or non-EU based) for the purposes of advancing management and treatment of diabetes.', 'infoTypes': ['STUDY_PROTOCOL', 'SAP'], 'timeFrame': 'Study protocol, statistical analysis plan and fully anonymised individual participant data that underlie the results reported in the manuscript will be available 6 months following publication and ending 36 months following manuscript publication to investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose, to achieve aims in the approved proposal. Proposals should be directed to rh347@cam.ac.uk and may be submitted up to 36 months following article publication.', 'accessCriteria': 'Study protocol, statistical analysis plan and fully anonymised individual participant data that underlie the results reported in the manuscript will be available 6 months following publication and ending 36 months following manuscript publication to investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose, to achieve aims in the approved proposal. Proposals should be directed to rh347@cam.ac.uk and may be submitted up to 36 months following article publication.'}}","{'miscInfoModule': {'versionHolder': '2026-01-02', 'removedCountries': ['Germany']}, 'conditionBrowseModule': {'meshes': [{'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}}",False,
